<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0">
<channel>
  <title>Society Health News</title>
  <link>http://www.lls.org</link>
  <language>en-us</language>

  <item>
  <title>Method of the Future Uses Single-Cell Imaging to Identify Gene Interactions</title>
  <pubDate>Tue, 09 Feb 2010 15:30:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=598246&amp;cat_id=140</link>
  <description><![CDATA[In a study published online in Genome Research, researchers have developed a novel method of interpreting data from single-cell images to identify genetic interactions within biological networks, offering a glimpse into the future of high-throughput cell imaging analysis.]]></description>
  </item>
  <item>
  <title>Stem Cell, Bone Marrow Transplants Both Benefit Leukemia Patients</title>
  <pubDate>Thu, 04 Feb 2010 13:43:37 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=597862&amp;cat_id=140</link>
  <description><![CDATA[Long-term survival rates are similar for leukemia patients who've had either peripheral blood stem cell (PBSC) or bone marrow transplants, a new European study says.]]></description>
  </item>
  <item>
  <title>Plant flavonoid may help prevent leukaemia - study</title>
  <pubDate>Thu, 04 Feb 2010 13:40:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=597859&amp;cat_id=140</link>
  <description><![CDATA[Eating foods like celery and parsley which contain the naturally occurring flavonoid apigenin may help prevent leukaemia, Dutch scientists said on Thursday.]]></description>
  </item>
  <item>
  <title>Bortezomib effective for some indolent non-Hodgkin&#39;s lymphomas</title>
  <pubDate>Thu, 04 Feb 2010 11:35:51 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=597847&amp;cat_id=140</link>
  <description><![CDATA[The proteasome inhibitor bortezomib (Velcade) is effective in patients with follicular lymphoma and other indolent non-Hodgkin's lymphomas, according to a report in the January 12th issue of Clinical Cancer Research.]]></description>
  </item>
  <item>
  <title>The Leukemia &amp; Lymphoma Society Increases Critical Benefit for Myeloma Patients</title>
  <pubDate>Tue, 02 Feb 2010 15:03:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=597680&amp;cat_id=140</link>
  <description><![CDATA[The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenström macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.]]></description>
  </item>
  <item>
  <title>Drug that Modifies Gene Activity Could Help Some Older Leukemia Patients</title>
  <pubDate>Wed, 20 Jan 2010 14:42:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=596668&amp;cat_id=140</link>
  <description><![CDATA[Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.]]></description>
  </item>
  <item>
  <title>Life expectancy favorable for 5-year stem-cell transplant survivors</title>
  <pubDate>Wed, 20 Jan 2010 14:39:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=596666&amp;cat_id=140</link>
  <description><![CDATA[Patients who survive for at least 5 years after hematopoietic cell transplantation without recurrence of their original disease are quite likely to survive for an additional 15 years, Washington-based researchers report in the January 11th online edition of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Decitabine helpful in elderly with leukemia</title>
  <pubDate>Thu, 07 Jan 2010 17:11:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595645&amp;cat_id=140</link>
  <description><![CDATA[A substantial minority of older patients with acute myeloid leukemia (AML) responds to first-line treatment with the nucleoside analogue decitabine, researchers report in a December 21st on-line paper in the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>New Target for Lymphoma Therapy</title>
  <pubDate>Thu, 07 Jan 2010 17:05:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595643&amp;cat_id=140</link>
  <description><![CDATA[Researchers at the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI) have found a link between a common mutation that can lead to cancer and a distant gene regulator that enhances its activity. Discovery of this relationship could lead to drugs targeting B-cell lymphomas, including Burkitt's lymphoma, an aggressive cancer in children, as well as multiple myelomas and other blood-related cancers.]]></description>
  </item>
  <item>
  <title>Dasatinib, nilotinib have similar favorable results against CML</title>
  <pubDate>Thu, 07 Jan 2010 17:01:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595641&amp;cat_id=140</link>
  <description><![CDATA[Patients with early chronic phase chronic myeloid leukemia (CML) have high response rates to either dasatinib (Sprycel) or nilotinib (Tasigna), according to two papers reported online December 14 in the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>High-risk elderly leukemia patients may respond to laromustine</title>
  <pubDate>Thu, 07 Jan 2010 17:00:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595639&amp;cat_id=140</link>
  <description><![CDATA[Nearly a third of elderly patients with untreated poor-risk acute myeloid leukemia (AML) responded to an infusion of laromustine, according to an online report in the December 21st Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Outcome of stem cell transplant for myelodysplastic syndrome unaffected by age</title>
  <pubDate>Thu, 07 Jan 2010 16:59:12 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595637&amp;cat_id=140</link>
  <description><![CDATA[Allogeneic hematopoietic stem-cell transplantation should be considered for patients 50 years or older with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia, according to a December 14th online publication in the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>New Test Could Discern Serious Condition Early After Bone Marrow Transplant</title>
  <pubDate>Thu, 07 Jan 2010 16:56:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595633&amp;cat_id=140</link>
  <description><![CDATA[A new blood test can discern whether a skin rash signals a high-risk complication or just a minor nuisance in people who have undergone a bone marrow transplant, researchers report in the Jan. 6 Science Translational Medicine.]]></description>
  </item>
  <item>
  <title>Human Trial for Leukemia Vaccine</title>
  <pubDate>Thu, 07 Jan 2010 16:53:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595631&amp;cat_id=140</link>
  <description><![CDATA[A new treatment for leukemia to stop the disease from returning following chemotherapy treatment or a bone marrow transplant has been developed by British researchers and will be now be available for patients in a clinical trial at King's College London.]]></description>
  </item>
  <item>
  <title>Leukemia: A Home Run and a Long Touchdown Drive</title>
  <pubDate>Tue, 05 Jan 2010 13:57:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=595443&amp;cat_id=140</link>
  <description><![CDATA[The landscape of progress in leukemia has several prominent landmarks, but specialists in the field agree that two tower above all others: the conquests of chronic myeloid leukemia (CML) in adults and childhood acute lymphocytic leukemia (ALL).]]></description>
  </item>
  <item>
  <title>Male infertility common among childhood cancer survivors</title>
  <pubDate>Thu, 10 Dec 2009 14:18:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594650&amp;cat_id=140</link>
  <description><![CDATA[Male survivors of childhood cancer are only about half as likely as their siblings to sire a pregnancy, according to a report from the Childhood Cancer Survivor Study in the November 30th issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Childhood ALL survivors at risk for neurologic sequelae</title>
  <pubDate>Thu, 10 Dec 2009 14:17:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594648&amp;cat_id=140</link>
  <description><![CDATA[Adults who are survivors of acute lymphoblastic leukemia (ALL) in childhood are at increased risk of late-onset sequelae including coordination problems and seizures, new research shows.]]></description>
  </item>
  <item>
  <title>Omacetaxine shows promise against hard-to-treat CML</title>
  <pubDate>Thu, 10 Dec 2009 14:16:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594645&amp;cat_id=140</link>
  <description><![CDATA[Omacetaxine, a first-in-class cetaxane, is an effective treatment for chronic myeloid leukemia (CML) associated with the Bcr-Abl T315I mutation, a form of the disease in which tyrosine kinase inhibitors are ineffective, new research shows.]]></description>
  </item>
  <item>
  <title>Blood Cancers: New Research Demonstrates Advances in Optimizing Treatments and Quality of Life</title>
  <pubDate>Thu, 10 Dec 2009 14:15:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594643&amp;cat_id=140</link>
  <description><![CDATA[There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.]]></description>
  </item>
  <item>
  <title>Kids Who Beat Cancer Still Face Heart Risks</title>
  <pubDate>Thu, 10 Dec 2009 14:13:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594641&amp;cat_id=140</link>
  <description><![CDATA[Survivors of childhood cancer have a significantly increased risk for developing heart disease as young adults, a new study finds.]]></description>
  </item>
  <item>
  <title>Multiple Myeloma Patients Experience High Response Rate with New 3-Drug Combination</title>
  <pubDate>Tue, 08 Dec 2009 12:30:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594488&amp;cat_id=140</link>
  <description><![CDATA[A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.]]></description>
  </item>
  <item>
  <title>Celator(R) Pharmaceuticals Presents Interim Data from Phase 2 Study of CPX-351 in Newly Diagnosed AML at American Society of Hematology Meeting</title>
  <pubDate>Tue, 08 Dec 2009 12:28:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594486&amp;cat_id=140</link>
  <description><![CDATA[Celator Pharmaceuticals announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at ASH.]]></description>
  </item>
  <item>
  <title>Carfilzomib shows promise in multiple myeloma study</title>
  <pubDate>Tue, 08 Dec 2009 12:24:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594484&amp;cat_id=140</link>
  <description><![CDATA[An experimental cancer drug has shown promising response rates in patients with relapsed and/or refractory multiple myeloma, according to interim data from a pair of small mid-stage trials.]]></description>
  </item>
  <item>
  <title>Celgene MM-015 trial cuts disease progress 50%</title>
  <pubDate>Tue, 08 Dec 2009 12:23:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594481&amp;cat_id=140</link>
  <description><![CDATA[Celgene Corp said on Monday that a trial of its cancer drug Revlimid, known as lenalidomide generically, showed it reduced the risk of disease progression in newly diagnosed patients with multiple myeloma by 50%.]]></description>
  </item>
  <item>
  <title>Cephalon&#39;s Treanda tops CHOP chemo in NHL</title>
  <pubDate>Tue, 08 Dec 2009 12:21:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=594479&amp;cat_id=140</link>
  <description><![CDATA[Cephalon Inc's Treanda, known generically as bendamustine, was significantly more effective and far less toxic than a standard CHOP chemotherapy regimen as an initial treatment for non-Hodgkin's lymphoma, according to data from a clinical trial presented on Monday.]]></description>
  </item>
  <item>
  <title>Researcher Behind the Drug Gleevec</title>
  <pubDate>Fri, 13 Nov 2009 16:07:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=593468&amp;cat_id=140</link>
  <description><![CDATA[Dr. Brian J. Druker, 54, an oncologist at Oregon Health and Sciences University and a Howard Hughes Medical Investigator, is one of three winners this year of the Lasker-DeBakey Clinical Medical Research Award, often called the "American Nobel Prize." Dr. Druker shared the honor with Nicholas B. Lydon, a former researcher for Novartis, and Charles L. Sawyers of Memorial Sloan-Kettering Cancer Center, "for the development of molecularly targeted treatments for chronic myeloid leukemia, converting a fatal cancer into a manageable chronic condition."]]></description>
  </item>
  <item>
  <title>Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma</title>
  <pubDate>Fri, 13 Nov 2009 16:05:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=593466&amp;cat_id=140</link>
  <description><![CDATA[New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online in Blood, the official journal of the American Society of Hematology.]]></description>
  </item>
  <item>
  <title>FDA Approves Drug Treatment for Rare Cancer</title>
  <pubDate>Tue, 10 Nov 2009 14:00:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=592478&amp;cat_id=140</link>
  <description><![CDATA[FDA approved romidepsin for injection (ISTODAXR) for the treatment of CTCL in patients who have received at least one prior systemic therapy]]></description>
  </item>
  <item>
  <title>First Use of Antibody and Stem Cell Transplantation to Successfully Treat Advanced Leukemia</title>
  <pubDate>Fri, 06 Nov 2009 14:22:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=592470&amp;cat_id=140</link>
  <description><![CDATA[For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.]]></description>
  </item>
  <item>
  <title>Lenalidomide/bortezomib safe, promising against relapsed multiple myeloma</title>
  <pubDate>Thu, 05 Nov 2009 11:53:06 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=592418&amp;cat_id=140</link>
  <description><![CDATA[The combination of the immunomodulatory drug lenalidomide and the proteasome inhibitor bortezomib appears to be both safe and potentially able to induce durable responses in patients with relapsed or relapsed/refractory multiple myeloma, U.S. researchers report online in the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Risk of thyroid cancer increased in childhood cancer survivors</title>
  <pubDate>Thu, 05 Nov 2009 11:47:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=592414&amp;cat_id=140</link>
  <description><![CDATA[Childhood cancer survivors are 18 times more likely to develop thyroid cancer than the general population, UK researchers report.]]></description>
  </item>
  <item>
  <title>Remission rate after first early ALL relapse better than expected in retrospective study</title>
  <pubDate>Thu, 05 Nov 2009 11:44:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=592412&amp;cat_id=140</link>
  <description><![CDATA[A retrospective study of children with acute lymphoblastic leukemia (ALL) suggests that the remission rate after first relapse may be higher than previously reported.]]></description>
  </item>
  <item>
  <title>FDA Approves New Treatment for Chronic Lymphocytic Leukemia</title>
  <pubDate>Wed, 28 Oct 2009 11:01:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591878&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.]]></description>
  </item>
  <item>
  <title>Survival for High Risk Childhood Leukemia More Than Doubled by New Treatment</title>
  <pubDate>Fri, 23 Oct 2009 15:42:43 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591655&amp;cat_id=140</link>
  <description><![CDATA[Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).]]></description>
  </item>
  <item>
  <title>Door Opens to Health Claims Tied to Agent Orange</title>
  <pubDate>Fri, 23 Oct 2009 15:41:19 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591652&amp;cat_id=140</link>
  <description><![CDATA[Under rules to be proposed this week, the Department of Veterans Affairs plans to add Parkinson's disease, ischemic heart disease and hairy-cell leukemia to the growing list of illnesses presumed to have been caused by Agent Orange, the toxic defoliant used widely in Vietnam.]]></description>
  </item>
  <item>
  <title>Research Puts a ‘Fas&#39; to the Cause of Programmed Cell Death</title>
  <pubDate>Fri, 23 Oct 2009 15:39:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591650&amp;cat_id=140</link>
  <description><![CDATA[Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also called apoptosis).]]></description>
  </item>
  <item>
  <title>Exercise eases fatigue in cancer patients on chemo</title>
  <pubDate>Fri, 23 Oct 2009 15:34:34 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591648&amp;cat_id=140</link>
  <description><![CDATA[Exercise can reduce the often debilitating fatigue that cancer patients experience during chemotherapy, new research shows.]]></description>
  </item>
  <item>
  <title>Balloon kyphoplasty effective for malignant spinal fractures</title>
  <pubDate>Fri, 23 Oct 2009 15:27:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591645&amp;cat_id=140</link>
  <description><![CDATA[Balloon kyphoplasty provides pain relief and functional improvement in patients with malignant spinal fractures, say researchers from Spain in the September 9th BMC Palliative Care.]]></description>
  </item>
  <item>
  <title>No major pregnancy complications seen in childhood cancer survivors</title>
  <pubDate>Fri, 23 Oct 2009 15:25:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591643&amp;cat_id=140</link>
  <description><![CDATA[Men and women who had cancer as children or adolescents are not generally at increased risk for major complications during pregnancy or for infant malformations or death, according to two papers in the Archives of Pediatrics and Adolescent Medicine for October.]]></description>
  </item>
  <item>
  <title>US FDA eyes possible risk with iron drug</title>
  <pubDate>Fri, 23 Oct 2009 15:23:37 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591641&amp;cat_id=140</link>
  <description><![CDATA[U.S. health officials are looking into whether patients with a certain bone marrow disorder are more at risk for death and serious complications with the drug Exjade, made by Novartis AG.]]></description>
  </item>
  <item>
  <title>Plerixafor enhances autologous stem-cell mobilization and transplantation</title>
  <pubDate>Fri, 23 Oct 2009 15:16:35 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591639&amp;cat_id=140</link>
  <description><![CDATA[When plerixafor is added to granulocyte colony-stimulating factor (G-CSF) and given to patients with non-Hodgkin's lymphoma, autologous stem-cell mobilization and transplantation are enhanced, according to a report in the October 1st Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Lipid screening recommended for radiation-treated Hodgkin&#39;s survivors</title>
  <pubDate>Fri, 23 Oct 2009 15:13:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591637&amp;cat_id=140</link>
  <description><![CDATA[Routine lipid screening, followed by treatment with statins when necessary, can likely reduce cardiac-related deaths in people who have survived Hodgkin's lymphoma after receiving mediastinal irradiation.]]></description>
  </item>
  <item>
  <title>Low-dose dexamethasone superior to high-dose for myeloma; trial stopped early</title>
  <pubDate>Thu, 22 Oct 2009 14:45:34 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591536&amp;cat_id=140</link>
  <description><![CDATA[In patients with newly diagnosed multiple myeloma, combining the thalidomide analog lenalidomide with low-dose dexamethasone led to better short-term survival than lenalidomide plus high-dose dexamethasone, along with fewer serious side effects.]]></description>
  </item>
  <item>
  <title>Study Shows How Normal Cells Influence Tumor Growth</title>
  <pubDate>Thu, 22 Oct 2009 14:43:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=591534&amp;cat_id=140</link>
  <description><![CDATA[It was once thought that the two communities of cells within a cancerous breast tumor -- fast-growing malignant cells and the normal cells that surround them -- existed independently, without interaction.]]></description>
  </item>
  <item>
  <title>Strategy for Mismatched Stem Cell Transplants Triggers Protection Against Graft-vs.-Host</title>
  <pubDate>Thu, 08 Oct 2009 13:29:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=590693&amp;cat_id=140</link>
  <description><![CDATA[A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute.]]></description>
  </item>
  <item>
  <title>Don&#39;t Let Insurance Restrictions Cripple Cancer Research</title>
  <pubDate>Thu, 08 Oct 2009 13:28:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=590695&amp;cat_id=140</link>
  <description><![CDATA[It is rare that Florida's lawmakers are called upon to support an issue that requires no legislative action. As Congress struggles in Washington to address the issue of health care, the Leukemia & Lymphoma Society and Humana Inc. urge our leaders in the Florida Legislature to support a health care issue that will prove to be a tremendous benefit to cancer patients, health care providers and insurers alike.]]></description>
  </item>
  <item>
  <title>Survival for High Risk Childhood Leukemia More Than Doubled by New Treatment</title>
  <pubDate>Thu, 08 Oct 2009 13:21:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=590690&amp;cat_id=140</link>
  <description><![CDATA[Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).]]></description>
  </item>
  <item>
  <title>FDA Panel Backs Allos Therapeutics&#39; Cancer Drug</title>
  <pubDate>Wed, 07 Oct 2009 15:18:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586594&amp;cat_id=140</link>
  <description><![CDATA[Federal health experts voted in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer.]]></description>
  </item>
  <item>
  <title>FDA Approves First Drug for Treatment of Peripheral T-cell Lymphoma</title>
  <pubDate>Fri, 25 Sep 2009 14:06:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=587259&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.]]></description>
  </item>
  <item>
  <title>New Research Strategy for Understanding Drug Resistance in Leukemia</title>
  <pubDate>Mon, 21 Sep 2009 15:00:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586592&amp;cat_id=140</link>
  <description><![CDATA[UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant.]]></description>
  </item>
  <item>
  <title>Researchers Identify Protein-Telomere Interactions That Could be Key in Treating Cancer</title>
  <pubDate>Mon, 21 Sep 2009 14:57:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586590&amp;cat_id=140</link>
  <description><![CDATA[A team of researchers from The Wistar Institute have shown that a large non-coding RNA in mammals and yeast plays a central role in helping maintain telomeres, the tips of chromosomes that contain important genetic information and help regulate cell division.]]></description>
  </item>
  <item>
  <title>Blood Thinner May Prevent Chemo-Related Clots</title>
  <pubDate>Mon, 21 Sep 2009 14:53:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586587&amp;cat_id=140</link>
  <description><![CDATA[Cancer patients who receive chemotherapy are more likely to develop blood clots than other people, but now a new study says a blood-thinning drug could cut the risk in half.]]></description>
  </item>
  <item>
  <title>Molecular ‘GPS&#39; Helps Researchers Probe Processes Important in Aging and Disease</title>
  <pubDate>Mon, 21 Sep 2009 14:51:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586584&amp;cat_id=140</link>
  <description><![CDATA[the buildup of oxygen radicals and other reactive oxygen species (ROS) in cells contributes to aging and possibly to diseases such as cancer and Alzheimer's. But in moderate amounts, ROS also help keep cells healthy by controlling cell division, movement and other normal biological processes.]]></description>
  </item>
  <item>
  <title>Anemic Patients with MDS Gain Long-Term Benefits from Erythropoietin and Myeloid Growth Factor Hormones</title>
  <pubDate>Mon, 21 Sep 2009 14:37:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586581&amp;cat_id=140</link>
  <description><![CDATA[A new study, however, demonstrates that MDS patients with anemia may benefit from treatment with an erythropoietin (EPO)-based regimen plus supportive care without added complications as compared with those receiving supportive care alone.]]></description>
  </item>
  <item>
  <title>For lymphoma, where you get care may affect outcome</title>
  <pubDate>Mon, 21 Sep 2009 14:33:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=586564&amp;cat_id=140</link>
  <description><![CDATA[Lymphoma patients' survival can depend on where they live, and where they get treated, a new study out in the Journal of Clinical Oncology shows.]]></description>
  </item>
  <item>
  <title>Drilling Down to Eliminate Cancer Disparities</title>
  <pubDate>Mon, 18 May 2009 15:29:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=555192&amp;cat_id=140</link>
  <description><![CDATA[Read about the work of Cheryl L. Willman, M.D., and LLS-funded researcher from New Mexico.]]></description>
  </item>
  <item>
  <title>LLS, Gap Inc. Encourage Shoppers to Support Cancer-Fighting Programs</title>
  <pubDate>Tue, 10 Mar 2009 09:19:43 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=557413&amp;cat_id=140</link>
  <description><![CDATA[The Leukemia & Lymphoma Society (LLS) today announced a partnership with Gap Inc. through its Give & Get program, to raise funds for LLS's blood cancer research, patient education and support initiatives.]]></description>
  </item>
  <item>
  <title>New Effort Brings Industry to Academia</title>
  <pubDate>Mon, 09 Mar 2009 13:47:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=557248&amp;cat_id=140</link>
  <description><![CDATA[The University of Kansas, with the help of LLS, is using a strategy to find and improve drugs, particularly those for cancer, that is more often found in a pharmaceutical company than in academia.]]></description>
  </item>
  <item>
  <title>Few Physicians Support Private Banking of Umbilical Cord Blood: Survey</title>
  <pubDate>Mon, 09 Mar 2009 13:41:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=557244&amp;cat_id=140</link>
  <description><![CDATA[A survey of physicians has found broad support for the position that parents should not bank their newborns' umbilical cord blood in a private blood bank unless another member of the family is at risk for a blood disease that will require a stem cell transplant. Read more.]]></description>
  </item>
  <item>
  <title>Bone Marrow Transplant Patients Fare Best with HLA-Identical Sibling Donors</title>
  <pubDate>Mon, 09 Mar 2009 09:23:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=557177&amp;cat_id=140</link>
  <description><![CDATA[Outcomes of bone marrow transplant (BMT) for chronic phase chronic myeloid leukemia (CML) are best with HLA-identical sibling donors, according to a report in the February 17th online issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Maintenance Rituximab Useful for Advanced Indolent Lymphoma</title>
  <pubDate>Tue, 03 Mar 2009 10:02:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=555946&amp;cat_id=140</link>
  <description><![CDATA[Maintenance rituximab following cyclophosphamide, vincristine, and prednisone (CVP) therapy can increase progression-free survival in patients with stage III-IV indolent lymphoma, according to a new report.]]></description>
  </item>
  <item>
  <title>Lymphocyte Count Predicts Survival after Relapse of Diffuse Large B-Cell Lymphoma</title>
  <pubDate>Wed, 25 Feb 2009 14:55:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=555195&amp;cat_id=140</link>
  <description><![CDATA[The peripheral blood absolute lymphocyte count (ALC) at the time of first relapse of diffuse large B-cell lymphoma (DLBCL) is a predictor of survival, according to a retrospective study by researchers at the Mayo Clinic, Rochester, Minnesota.]]></description>
  </item>
  <item>
  <title>&#34;Watch and Wait&#34; Sometimes a Viable Option in Mantle-Cell Lymphoma</title>
  <pubDate>Mon, 23 Feb 2009 13:02:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=554852&amp;cat_id=140</link>
  <description><![CDATA[Although treatment immediately following diagnosis is common in patients with mantle-cell lymphoma (MCL), up to one-third of MCL cases may follow an indolent course, according to a retrospective analysis by U.S. researchers published online by the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Partially Matched Cord Blood a Good Option for Transplantation in Children</title>
  <pubDate>Thu, 19 Feb 2009 10:17:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=554174&amp;cat_id=140</link>
  <description><![CDATA[Children in need of myeloablative stem cell transplantation do well with unrelated, partially matched cord blood as an alternative to matched cord blood or bone marrow, according to research presented at the annual meeting of the American Society of Bone Marrow Transplantation.]]></description>
  </item>
  <item>
  <title>MRSA Central Line-Related Bloodstream Infections Falling in U.S. Critical Care Units</title>
  <pubDate>Wed, 18 Feb 2009 11:33:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=553798&amp;cat_id=140</link>
  <description><![CDATA[The rate of methicillin-resistant Staphylococcus aureus (MRSA) central line-associated bloodstream infections in US intensive care units has been dropping, according to a new report.]]></description>
  </item>
  <item>
  <title>Green Tea May Block Activity of Bortezomib (Velcade)</title>
  <pubDate>Thu, 12 Feb 2009 09:33:34 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=552974&amp;cat_id=140</link>
  <description><![CDATA[New research suggests that the polyphenols in green tea are capable of negating the anti-cancer activity of bortezomib, a boronic acid-based proteasome inhibitor used for multiple myeloma.]]></description>
  </item>
  <item>
  <title>Medicare Covers More Off-Label Uses of Cancer Drugs</title>
  <pubDate>Mon, 09 Feb 2009 17:25:45 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=550943&amp;cat_id=140</link>
  <description><![CDATA[Medicare has expanded its coverage of drugs for cancer treatments not approved by the U.S. Food and Drug Administration. Cancer doctors had clamored for the changes, saying that some of these treatments, known as off-label uses, were essential if patients were to receive the most up-to-date care.]]></description>
  </item>
  <item>
  <title>Booklet Helps Cancer Patients Navigate Costly Care</title>
  <pubDate>Mon, 09 Feb 2009 17:24:43 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=552544&amp;cat_id=140</link>
  <description><![CDATA[The American Society of Clinical Oncology (ASCO) has released a guide to help cancer patients and their doctors communicate more effectively about the costs associated with their treatment and care.]]></description>
  </item>
  <item>
  <title>Research to Provide Information of Long-Term Effects of Childhood Cancer Treatment to Parents</title>
  <pubDate>Thu, 05 Feb 2009 13:29:42 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=552048&amp;cat_id=140</link>
  <description><![CDATA[Researchers have published findings on parents' needs for information about the neurocognitive late effects of treatment for childhood cancer. More.]]></description>
  </item>
  <item>
  <title>Cancer Survivors Often Forgo Needed Care Due to Cost Concerns</title>
  <pubDate>Thu, 05 Feb 2009 11:28:43 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=552004&amp;cat_id=140</link>
  <description><![CDATA[Even with health insurance, more than one million cancer survivors living in the United States report that they forgo needed medical care because of concerns about cost, according to research presented Wednesday at the American Association for Cancer Research conference on the Science of Health Care Disparities.]]></description>
  </item>
  <item>
  <title>Rising Cancer Drug Costs Not Fully Controllable Under Medicare</title>
  <pubDate>Thu, 29 Jan 2009 12:41:32 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=551288&amp;cat_id=140</link>
  <description><![CDATA[Current regulations are limiting Medicare's ability to control rising spending on cancer drugs, concludes the author of a Health Policy Report published Online First (January 28) in The New England Journal of Medicine.]]></description>
  </item>
  <item>
  <title>Adults with ALL Benefit from Pediatric-Type Intensive Chemotherapy</title>
  <pubDate>Thu, 29 Jan 2009 09:07:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=551207&amp;cat_id=140</link>
  <description><![CDATA[Pediatric-inspired chemotherapy markedly improves the outcome of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), at least up to the age of 45 years. This finding comes from a multicenter phase II study by the Group for Research on Adult Acute Lymphoblastic Leukemia, a French/Swiss/Belgian consortium, and is published online by the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Childhood Cancer Survivors Miss Needed Mammograms</title>
  <pubDate>Wed, 28 Jan 2009 10:12:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=551071&amp;cat_id=140</link>
  <description><![CDATA[Women who were treated with chest radiation for childhood cancer are at increased risk of early breast cancer, but many are not getting the screening tests experts recommend, researchers reported Tuesday.]]></description>
  </item>
  <item>
  <title>Small Biotechs Increasingly Seek Funds from Nonprofit Groups</title>
  <pubDate>Fri, 23 Jan 2009 11:16:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=550572&amp;cat_id=140</link>
  <description><![CDATA[Small biotechnology companies are increasingly turning to nonprofit groups such as The Leukemia & Lymphona Society for alternative sources of money.  Read more.]]></description>
  </item>
  <item>
  <title>Hospitals Demanding Cash Up Front</title>
  <pubDate>Fri, 23 Jan 2009 11:11:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=550570&amp;cat_id=140</link>
  <description><![CDATA[Nearly 4,200 out of the nation's 4,900 hospitals are beginning to require proof of payment up front for non-emergency needs. Meaning: if it is care you can schedule, the hospital wants to know how you will pay for it.]]></description>
  </item>
  <item>
  <title>Prophylactic Acyclovir Prevents Herpes Zoster Outbreaks During Bortezomib Treatment</title>
  <pubDate>Fri, 23 Jan 2009 09:41:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=550556&amp;cat_id=140</link>
  <description><![CDATA[Patients with multiple myeloma who are receiving bortezomib therapy benefit from prophylactic acyclovir, which effectively and completely prevents reactivation of the varicella (herpes) zoster virus, according the researchers at Northwestern University in Chicago.]]></description>
  </item>
  <item>
  <title>Tandem Autologous Hematopoietic Cell Transplants Do Not Improve Multiple Myeloma Outcomes</title>
  <pubDate>Wed, 21 Jan 2009 09:51:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=550202&amp;cat_id=140</link>
  <description><![CDATA[Tandem autologous hematopoietic cell transplantation (AHCT) for multiple myeloma does not improve survival over that provided by single AHCT, according to a meta-analysis published in the January 21st Journal of the National Cancer Institute.]]></description>
  </item>
  <item>
  <title>Clinical Trial May Lead to More Effective Treatment for Blood Cancers</title>
  <pubDate>Fri, 16 Jan 2009 12:19:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=549725&amp;cat_id=140</link>
  <description><![CDATA[Researchers with the Indiana University Melvin and Bren Simon Cancer Center want to find a way to speed up the growth of new cells following umbilical cord blood transplants in adult patients with blood cancers. Read more.]]></description>
  </item>
  <item>
  <title>Americans Spending More on Healthcare: Report</title>
  <pubDate>Wed, 14 Jan 2009 10:10:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=549241&amp;cat_id=140</link>
  <description><![CDATA[Americans spent about 40 percent more out of their own pockets for healthcare over the past decade, according to a report in the latest issue of the health policy journal Health Affairs. An increase in chronic conditions, especially diabetes and high blood pressure -- not just among the "oldest old" but among baby boomers and older adults -- is to blame, researchers say.]]></description>
  </item>
  <item>
  <title>Palonosetron Useful for Preventing Vomiting During Chemotherapy</title>
  <pubDate>Mon, 12 Jan 2009 11:06:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548908&amp;cat_id=140</link>
  <description><![CDATA[Combined with dexamethasone, palonosetron is comparable to granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in the acute phase and superior to granisetron in the delayed phase, new research shows.]]></description>
  </item>
  <item>
  <title>Pain Intensity Predicts Complexity of Cancer Pain Management</title>
  <pubDate>Mon, 12 Jan 2009 11:05:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548906&amp;cat_id=140</link>
  <description><![CDATA[Pain intensity at initial assessment is significantly predictive of pain management complexity and length of time to stable pain control in patients with cancer, according to researchers.]]></description>
  </item>
  <item>
  <title>Healthcare Overhaul Need Not Break Bank: Study</title>
  <pubDate>Mon, 12 Jan 2009 09:58:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548897&amp;cat_id=140</link>
  <description><![CDATA[An analysis of proposals to overhaul U.S. health care by President-elect Barack Obama and members of Congress suggests it is possible to insure all Americans without significantly raising total health spending.]]></description>
  </item>
  <item>
  <title>Oral Bisphosphonate Use Linked to Jaw Osteonecrosis</title>
  <pubDate>Mon, 12 Jan 2009 09:57:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548895&amp;cat_id=140</link>
  <description><![CDATA[Oral treatment with the bisphosphonate alendronate (Fosamax, Merck) for as little as 1 year increases the risk for osteonecrosis of the jaw following certain dental procedures, according to a study conducted at the University of Southern California School of Dentistry in Los Angeles.]]></description>
  </item>
  <item>
  <title>Study Unlocks Mystery of Child Leukemia Relapse</title>
  <pubDate>Fri, 09 Jan 2009 09:42:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548676&amp;cat_id=140</link>
  <description><![CDATA[A certain gene abnormality raises the chance of relapse for children with the most common form of childhood cancer, a discovery that could change the way doctors treat them, U.S. researchers said on Wednesday]]></description>
  </item>
  <item>
  <title>Medicare Proposes Wider Cancer Scan Coverage</title>
  <pubDate>Thu, 08 Jan 2009 11:48:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548511&amp;cat_id=140</link>
  <description><![CDATA[U.S. health officials proposed paying for wider use of PET scans to help doctors decide the initial course of treatment in some cancer patients, the Centers for Medicare & Medicaid Services said on Tuesday.]]></description>
  </item>
  <item>
  <title>Debate: Should Patients Be Told of Better Cancer Care Elsewhere?</title>
  <pubDate>Tue, 06 Jan 2009 15:56:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548205&amp;cat_id=140</link>
  <description><![CDATA[Read more about this important medical debate in a New York Times article.]]></description>
  </item>
  <item>
  <title>The Maker of Miracles</title>
  <pubDate>Tue, 06 Jan 2009 12:42:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548085&amp;cat_id=140</link>
  <description><![CDATA[For Brian Druker, M.D., innovation requires putting up with grueling work hours and taking some big risks.]]></description>
  </item>
  <item>
  <title>Genetic Tests Offer Promise of Personalized Medicine</title>
  <pubDate>Tue, 06 Jan 2009 12:39:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548089&amp;cat_id=140</link>
  <description><![CDATA[Read more about this interesting research.]]></description>
  </item>
  <item>
  <title>Novel Pathway Involved in Therapy-Resistant Cancers Discovered</title>
  <pubDate>Tue, 06 Jan 2009 12:36:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=548087&amp;cat_id=140</link>
  <description><![CDATA[Scientists at The Babraham Institute have begun to unpick the complex mechanisms underpinning the development of drug resistant cancers.]]></description>
  </item>
  <item>
  <title>Honey, You&#39;re Really Sick</title>
  <pubDate>Fri, 19 Dec 2008 12:07:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546980&amp;cat_id=140</link>
  <description><![CDATA[When it comes time to tell a child he or she has cancer or some other devastating disease, many parents try to skirt the issue.]]></description>
  </item>
  <item>
  <title>FDA Approves Plerixafor for Use in Autologous Transplants</title>
  <pubDate>Fri, 19 Dec 2008 09:47:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546955&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved plerixafor (Mozobil™) solution for use in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. More.]]></description>
  </item>
  <item>
  <title>Partially Matched Cord Blood Suitable for Urgent Transplant in Adults with Leukemia</title>
  <pubDate>Wed, 17 Dec 2008 15:41:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546600&amp;cat_id=140</link>
  <description><![CDATA[Mismatched unrelated cord blood transplant may be an effective alternative to mismatched bone marrow or peripheral blood transplants.]]></description>
  </item>
  <item>
  <title>Sirolimus Improves Lymphoma Survival in Stem Cell Recipients</title>
  <pubDate>Wed, 17 Dec 2008 09:20:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546532&amp;cat_id=140</link>
  <description><![CDATA[Lymphoma patients receiving sirolimus for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem-cell transplantation (HSCT) with reduced-intensity conditioning, appear to have a lower risk of disease progression, researchers report in an advance on-line issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Intense Chemotherapy Wards off Recurrence in Half of Mantle Cell Lymphoma Patients after Seven Years</title>
  <pubDate>Tue, 16 Dec 2008 12:06:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546365&amp;cat_id=140</link>
  <description><![CDATA[More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report.]]></description>
  </item>
  <item>
  <title>Stem Cell Transplant Effective against Peripheral T-Cell Lymphomas</title>
  <pubDate>Tue, 16 Dec 2008 12:03:19 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546349&amp;cat_id=140</link>
  <description><![CDATA[Myeloablative therapy and autologous stem-cell transplantation may offer an effective strategy for the treatment of patients with peripheral T-cell lymphomas (PTCLs), German researchers report in an advance on-line publication in the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Epratuzumab Plus Rituximab Effective in Recurrent Non-Hodgkin Lymphoma</title>
  <pubDate>Mon, 15 Dec 2008 09:44:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=546134&amp;cat_id=140</link>
  <description><![CDATA[Combination therapy with the anti-CD22 monoclonal antibody epratuzumab and the anti-CD20 monoclonal antibody rituximab was well tolerated and achieved a durable response in patients with post-chemotherapy relapsed/refractory, indolent non-Hodgkin lymphoma (NHL), results of an international multicenter trial show.]]></description>
  </item>
  <item>
  <title>New Data on Vorinostat in Combination with Bortezomib for Myeloma</title>
  <pubDate>Wed, 10 Dec 2008 16:33:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545757&amp;cat_id=140</link>
  <description><![CDATA[Results from two Phase I studies of vorinostat (Zolinza®), an oral histone deacetylase inhibitor, administered in combination with bortezomib (Velcade®), showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.]]></description>
  </item>
  <item>
  <title>Potential Breakthrough for T-Cell Lymphoma Patients with Drug that Mimics Folic Acid</title>
  <pubDate>Wed, 10 Dec 2008 13:34:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545721&amp;cat_id=140</link>
  <description><![CDATA[Preliminary results of a pivotal Phase II clinical trial of pralatrexate, a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma. More.]]></description>
  </item>
  <item>
  <title>Drug Combination Improves or Stabilizes Disease for Relapsed Multiple Myeloma Patients</title>
  <pubDate>Wed, 10 Dec 2008 13:32:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545719&amp;cat_id=140</link>
  <description><![CDATA[Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment. More.]]></description>
  </item>
  <item>
  <title>Transplantation Outcomes for Leukemia Not Impaired by Obesity</title>
  <pubDate>Wed, 10 Dec 2008 09:49:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545686&amp;cat_id=140</link>
  <description><![CDATA[Overweight and obese adults who undergo myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia generally fare just as well as their normal-weight counterparts, according to study findings presented at the American Society of Hematology annual meeting in San Francisco.]]></description>
  </item>
  <item>
  <title>Older Age Does Not Affect Survival after Bone Marrow Transplant</title>
  <pubDate>Tue, 09 Dec 2008 17:27:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545654&amp;cat_id=140</link>
  <description><![CDATA[Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers report.]]></description>
  </item>
  <item>
  <title>Pre-Transplant Expansion of Umbilical Cord Blood Stem Cells Safe</title>
  <pubDate>Tue, 09 Dec 2008 17:24:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545651&amp;cat_id=140</link>
  <description><![CDATA[Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported.]]></description>
  </item>
  <item>
  <title>Novel Treatments Demonstrate Improvements in Overall Survival, Response Rates in Hard-to-Treat Leukemias, Lymphomas</title>
  <pubDate>Tue, 09 Dec 2008 12:38:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=545616&amp;cat_id=140</link>
  <description><![CDATA[Read more about promising research presented at the recent American Society of Hematology annual meeting.]]></description>
  </item>
  <item>
  <title>Adult Survivors of Childhood Leukemia Have Lower Bone Mineral Density, Study Finds</title>
  <pubDate>Thu, 04 Dec 2008 11:37:37 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=544206&amp;cat_id=140</link>
  <description><![CDATA[Men who survived childhood leukemia treatment into adulthood were more likely to have low bone mineral density than other adults their age, putting them at risk of osteoporosis and bone fractures, according to a new study.]]></description>
  </item>
  <item>
  <title>LLS and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial</title>
  <pubDate>Thu, 04 Dec 2008 11:35:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=544204&amp;cat_id=140</link>
  <description><![CDATA[LLS and Memgen LLC have jointly announced the beginning of a new clinical trial of the vaccine ISF35 at the University of California, San Diego (UCSD).]]></description>
  </item>
  <item>
  <title>Negative PET Scans Predicted High PFS in Advanced-Stage Hodgkin Lymphoma</title>
  <pubDate>Tue, 02 Dec 2008 12:09:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=543841&amp;cat_id=140</link>
  <description><![CDATA[PET has a high negative predictive value for progression and relapse among patients with advanced-stage Hodgkin lymphoma who have residual disease following chemotherapy.]]></description>
  </item>
  <item>
  <title>Modern Cancer Drugs More Likely to Get to Market</title>
  <pubDate>Mon, 17 Nov 2008 10:23:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=542073&amp;cat_id=140</link>
  <description><![CDATA[Nearly one in five cancer drugs entering development now reach the market, a remarkably good success rate given the high level of failures in other disease areas, British researchers said on Friday.]]></description>
  </item>
  <item>
  <title>Going to the Doctor? Go Prepared, Expert Advises</title>
  <pubDate>Wed, 12 Nov 2008 13:11:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=541714&amp;cat_id=140</link>
  <description><![CDATA[To make the most of your next visit to the doctor -- be prepared, proactive and "pleasantly assertive," Dr. Michael Pignone, chief of general internal medicine at University of North Carolina at Chapel Hill advises.]]></description>
  </item>
  <item>
  <title>Researchers Find Tests and Early Treatment Delay Progression of CLL</title>
  <pubDate>Mon, 10 Nov 2008 11:10:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=541224&amp;cat_id=140</link>
  <description><![CDATA[Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for chronic lymphocytic leukemia (CLL).]]></description>
  </item>
  <item>
  <title>Drug Treanda Approved for Non-Hodgkin Lymphoma</title>
  <pubDate>Tue, 04 Nov 2008 13:00:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=537915&amp;cat_id=140</link>
  <description><![CDATA[On Oct. 31, the U.S. Food and Drug Administration (FDA) approved bendamustine hydrochloride (Treanda®, Cephalon, Inc.), an intravenously administered alkylating agent, for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.]]></description>
  </item>
  <item>
  <title>Oocytes from Young Girls Can Be Cryopreserved Prior to Cancer Treatment</title>
  <pubDate>Tue, 04 Nov 2008 08:10:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=537835&amp;cat_id=140</link>
  <description><![CDATA[Young age does not preclude fertility-preservation efforts for girls undergoing gonadotoxic cancer treatment, through cryopreservation of isolated oocytes as well as ovarian cortex, a team in Israel reports in the October 27 online edition of Fertility and Sterility.]]></description>
  </item>
  <item>
  <title>C. Difficile Infection Often Seen in Leukemia Patients after Stem Cell Therapy</title>
  <pubDate>Tue, 28 Oct 2008 14:19:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=536534&amp;cat_id=140</link>
  <description><![CDATA[The results of a small study suggest that nearly a third of patients who undergo allogeneic hematopoietic stem cell transplantation will develop Clostridium difficile infection, and that those with leukemia are at much greater risk than patients with lymphoma.]]></description>
  </item>
  <item>
  <title>U.S. Panel Urges More Cancer Research Funding</title>
  <pubDate>Fri, 24 Oct 2008 09:30:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=536055&amp;cat_id=140</link>
  <description><![CDATA[The U.S. government needs to step up funding for cancer research, which has stagnated this decade, as part of an effort to make beating cancer a national priority, a presidential advisory panel said on Thursday.]]></description>
  </item>
  <item>
  <title>FDA Approves Ontak for Cutaneous T-Cell Lymphoma</title>
  <pubDate>Thu, 23 Oct 2008 09:53:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=535856&amp;cat_id=140</link>
  <description><![CDATA[On October 15, 2008, the U. S. Food and Drug Administration converted the approval of denileukin diftitox (Ontak®, Eisai Medical Research) solution for intravenous use for the treatment of persistent or recurrent CD-25 positive cutaneous T-cell lymphoma from accelerated approval to regular approval following confirmation of an improvement in progression-free survival (PFS) and overall response rate (ORR).  Denileukin diftitox was originally approved in 1999 under the accelerated approval program for this indication based on durable, objective responses in an open-label study comparing two different doses.  A further description of the FDA accelerated approval regulations is at http://www.fda.gov/cder/guidance/5645fnl.htm.]]></description>
  </item>
  <item>
  <title>Non-Hodgkin Lymphoma Incidence and Mortality in Europe Beginning to Level Off</title>
  <pubDate>Tue, 21 Oct 2008 09:39:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=535597&amp;cat_id=140</link>
  <description><![CDATA[The upward trend in the incidence and mortality of non-Hodgkin lymphoma (NHL) seen during the later part of the 20th century has now started to level off or decline in Europe and other developed countries.]]></description>
  </item>
  <item>
  <title>Risk-Based Care Lacking for Most Childhood Cancer Survivors</title>
  <pubDate>Mon, 20 Oct 2008 09:37:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=535473&amp;cat_id=140</link>
  <description><![CDATA[While the majority of survivors of childhood cancer receive regular medical care, few receive care focused on the specific risks resulting from their prior cancer therapy, according to findings published in the September 20th issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Pregnancy Rates High with ICSI Using Cryopreserved Sperm from Men with Cancer</title>
  <pubDate>Wed, 15 Oct 2008 10:10:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=534937&amp;cat_id=140</link>
  <description><![CDATA[High pregnancy rates can be achieved after in vitro fertilization via intracytoplasmic sperm injection (ICSI) using sperm cryopreserved before treatment of malignancy in men, according to a report in the September issue of Fertility and Sterility.]]></description>
  </item>
  <item>
  <title>Adding Cytarabine to Clofarabine Induction Improves Response Rate in AML</title>
  <pubDate>Mon, 13 Oct 2008 17:34:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=534751&amp;cat_id=140</link>
  <description><![CDATA[Clofarabine plus low-dose cytarabine achieves better response rates than clofarabine alone when used as front-line therapy for older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), according to a report in the September 1st issue of the journal Blood.]]></description>
  </item>
  <item>
  <title>End-of-Life Talk Has Cascading Benefits: Study</title>
  <pubDate>Wed, 08 Oct 2008 10:49:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=534193&amp;cat_id=140</link>
  <description><![CDATA[In terminally ill patients, "end-of-life" discussions with their doctor do not increase emotional distress or reduce quality of life, a study shows. On the contrary, these discussions improve the quality of life of both the patient and loved ones when death is near.]]></description>
  </item>
  <item>
  <title>Improving Diagnosis of Juvenile Myelomonocytic Leukemia</title>
  <pubDate>Tue, 07 Oct 2008 14:22:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=533997&amp;cat_id=140</link>
  <description><![CDATA[Using improved flow cytometry, researchers have identified an abnormal signaling signature in patients with juvenile myelomonocytic leukemia, which they believe could allow for a more rapid and accurate diagnosis of the condition.]]></description>
  </item>
  <item>
  <title>High-Dose Therapy and Stem Cell Transplant Useful for Resistant Hodgkin Lymphoma</title>
  <pubDate>Fri, 03 Oct 2008 12:36:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=533653&amp;cat_id=140</link>
  <description><![CDATA[High-dose therapy (HDT) combined with autologous stem cell transplantation (ASCT) may prolong remissions and improve survival in patients with chemoresistant Hodgkin lymphoma, researchers from Seattle report.]]></description>
  </item>
  <item>
  <title>Searching for Clarity: A Primer on Medical Studies</title>
  <pubDate>Tue, 30 Sep 2008 15:17:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=533371&amp;cat_id=140</link>
  <description><![CDATA[xx]]></description>
  </item>
  <item>
  <title>Most Radiation Oncology Patients Do Not Use Analgesics: Study</title>
  <pubDate>Tue, 30 Sep 2008 11:42:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=533333&amp;cat_id=140</link>
  <description><![CDATA[The results of a new study indicate that 80% of cancer patients undergoing radiation therapy do not use medications to combat pain.]]></description>
  </item>
  <item>
  <title>Lenalidomide May Cause Rare Skin Reactions in Some Patients</title>
  <pubDate>Fri, 19 Sep 2008 12:28:52 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=532223&amp;cat_id=140</link>
  <description><![CDATA[Lenalidomide (Revlimid) may cause Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme in some patients. The drug is a derivative of thalidomide and is used to treat myeloma.]]></description>
  </item>
  <item>
  <title>Supplemental Iron Improves Treatment Response in Chemotherapy-Induced Anemia</title>
  <pubDate>Tue, 16 Sep 2008 09:43:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=531678&amp;cat_id=140</link>
  <description><![CDATA[Intravenous (IV) iron strengthens and accelerates the response to the erythypoiesis-stimulating agent darbepoetin alfa in patients with chemotherapy-induced anemia (CIA), researchers announced here at the 33rd Congress of the European Society for Medical Oncology (ESMO).]]></description>
  </item>
  <item>
  <title>Cancer Stem Cells: Root of All Evil?</title>
  <pubDate>Fri, 12 Sep 2008 12:35:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=531467&amp;cat_id=140</link>
  <description><![CDATA[Cancer may be caused by stem cells gone bad. If that proves to be correct, it could revolutionise treatment.]]></description>
  </item>
  <item>
  <title>Survival Rates Rise in Childhood Blood Cancers</title>
  <pubDate>Fri, 12 Sep 2008 10:29:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=531443&amp;cat_id=140</link>
  <description><![CDATA[Survival rates have improved in the United States for children with three common types of blood cancer since the 1990s, thanks to improved treatment, researchers in Germany said on Tuesday.]]></description>
  </item>
  <item>
  <title>Dasatinib Active against Ph+ Leukemia with CNS Involvement</title>
  <pubDate>Mon, 08 Sep 2008 13:32:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530571&amp;cat_id=140</link>
  <description><![CDATA[Dasatinib, a second-generation dual-specific BCR-ABL kinase inhibitor, penetrates the blood-brain barrier and has promising therapeutic potential for Philadelphia chromosome-positive leukemia that has spread to the CNS, researchers report in the August 15 issue of the journal Blood.]]></description>
  </item>
  <item>
  <title>U.S. Food and Drug Administration Demands Tougher Warnings on Immunosuppressive Drugs</title>
  <pubDate>Fri, 05 Sep 2008 14:15:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530415&amp;cat_id=140</link>
  <description><![CDATA[Federal health authorities have asked the manufacturers of four widely used immunosuppressive drugs to bolster safety warnings on the risk of developing opportunistic fungal infections.]]></description>
  </item>
  <item>
  <title>Pregnancy and Cancer</title>
  <pubDate>Fri, 05 Sep 2008 10:55:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530364&amp;cat_id=140</link>
  <description><![CDATA[Read this interesting New York Times article on pregnancy and cancer.]]></description>
  </item>
  <item>
  <title>Rituximab Combo Active against Chronic Lymphocytic Leukemia</title>
  <pubDate>Fri, 05 Sep 2008 10:26:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530361&amp;cat_id=140</link>
  <description><![CDATA[A follow-up study of patients with chronic lymphocytic leukemia (CLL) shows that the initial success of a fludarabine, cyclophosphamide, and rituximab regimen is maintained in the long term, Houston-based researchers report in the August 15th issue of Blood.]]></description>
  </item>
  <item>
  <title>Tobacco Caused 2.4 million U.S. Cancers</title>
  <pubDate>Fri, 05 Sep 2008 10:24:51 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530359&amp;cat_id=140</link>
  <description><![CDATA[Tobacco use caused 2.4 million cases of cancer in the United States from 1999 to 2004, the Centers for Disease Control and Prevention reported on Thursday.]]></description>
  </item>
  <item>
  <title>Location, Location, Location Important for Genes, Too</title>
  <pubDate>Tue, 02 Sep 2008 16:06:32 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=530117&amp;cat_id=140</link>
  <description><![CDATA[To better understand how cells become cancerous, a new study at The Ohio State University's Comprehensive Cancer Center looks at four genes that help regulate cell growth in embryos and that contribute to cancer in adults.]]></description>
  </item>
  <item>
  <title>Combination Therapy Helps Combat Myeloma</title>
  <pubDate>Thu, 28 Aug 2008 12:22:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=529579&amp;cat_id=140</link>
  <description><![CDATA[Patients with multiple myeloma who could not tolerate high-dose chemotherapy lived longer and better by adding Velcade® to standard treatment, a new study found.]]></description>
  </item>
  <item>
  <title>Maintenance Rituximab Cost-Effective for Follicular Lymphoma</title>
  <pubDate>Wed, 27 Aug 2008 16:59:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=528947&amp;cat_id=140</link>
  <description><![CDATA[Continued treatment with rituximab appears to be cost-effective, as well as safe and effective, in the treatment of follicular lymphoma, a form of low-grade non-Hodgkin lymphoma.]]></description>
  </item>
  <item>
  <title>Cancer Drug May Help in Stroke Treatment</title>
  <pubDate>Fri, 22 Aug 2008 14:41:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=528467&amp;cat_id=140</link>
  <description><![CDATA[Researchers have found that the drug Gleevec may help in stroke treatment]]></description>
  </item>
  <item>
  <title>Reduced-Toxicity Conditioning Increases Success of Stem Cell Transplant</title>
  <pubDate>Fri, 22 Aug 2008 14:39:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=528465&amp;cat_id=140</link>
  <description><![CDATA[Reduced-toxicity conditioning can improve the outcomes of allogeneic hematopoietic cell transplantation candidates with advanced hematologic malignancies and older patients with more comorbidities, according to German researchers.]]></description>
  </item>
  <item>
  <title>Questions Patients Should Ask About Cancer Treatment</title>
  <pubDate>Tue, 19 Aug 2008 16:17:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=527941&amp;cat_id=140</link>
  <description><![CDATA[Patients armed with clear-cut facts are often able to make wiser choices about their care. Read more.]]></description>
  </item>
  <item>
  <title>Cladribine Achieves High Response Rates in Mantle Cell Lymphoma</title>
  <pubDate>Thu, 07 Aug 2008 16:20:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526713&amp;cat_id=140</link>
  <description><![CDATA[The purine nucleoside analogue cladribine (2-CDA) achieves high response rates and significantly improves survival in elderly patients with mantle cell lymphoma, even in those with recurrent disease, according to a report in the July 1 issue of Cancer.]]></description>
  </item>
  <item>
  <title>Studies Show People Underestimate Willingness of Others to Help Out</title>
  <pubDate>Thu, 07 Aug 2008 16:18:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526711&amp;cat_id=140</link>
  <description><![CDATA[For many, the thought of asking someone for help or a favor - such as a colleague, friend or stranger - is filled with discomfort. A series of studies, however, reveals that people tend to grossly underestimate how likely others are to agree to requests for assistance.]]></description>
  </item>
  <item>
  <title>Treatment with Anti-Anemia Drugs May Not Be Safe for Multiple Myeloma Patients</title>
  <pubDate>Thu, 07 Aug 2008 16:13:20 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526706&amp;cat_id=140</link>
  <description><![CDATA[A recent study in the American Journal of Hematology demonstrated that erythropoiesis-stimulating agents, a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients. Read more.]]></description>
  </item>
  <item>
  <title>Hypertension Potentiates the Risk of Doxorubicin Cardiotoxicity</title>
  <pubDate>Thu, 07 Aug 2008 16:10:51 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526704&amp;cat_id=140</link>
  <description><![CDATA[Doxorubicin is often withheld from older patients because advanced age -- along with heart disease, diabetes, and hypertension -- are known to increase the risk of doxorubicin-related cardiotoxicity. Now, in a study of older adults with diffuse large B-cell lymphoma (DLBCL), researchers have found that of all these factors, only hypertension synergistically potentiates the risk of cardiac effects.]]></description>
  </item>
  <item>
  <title>U.S. FDA Orders Amgen to Add New Anemia Drug Warning</title>
  <pubDate>Thu, 07 Aug 2008 16:08:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526702&amp;cat_id=140</link>
  <description><![CDATA[U.S. health officials ordered Amgen Inc on Wednesday to add new warnings to its widely used anemia drug Aranesp and similar medicines about the serious risks to cancer patients.]]></description>
  </item>
  <item>
  <title>HIV Patients Still at High Risk of Cancer</title>
  <pubDate>Thu, 07 Aug 2008 16:06:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526699&amp;cat_id=140</link>
  <description><![CDATA[Although there has been a reduction in the incidence of some AIDS-defining cancers in people with HIV infection, there has been an increase in certain other cancers, researchers report in the July 1st issue of the International Journal of Cancer.]]></description>
  </item>
  <item>
  <title>LLS Launches TrialCheck to Connect Patients to Cancer Clinical Trials</title>
  <pubDate>Thu, 07 Aug 2008 10:02:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=526497&amp;cat_id=140</link>
  <description><![CDATA[The Leukemia & Lymphoma Society (LLS) and the Coalition of Cancer Cooperative Groups (Coalition) today announced the launch of TrialCheck® as the exclusive search tool to assist patients and their caregivers in locating cancer clinical trials.  The collaboration gives patients and caregivers who visit the LLS Web site (www.lls.org/clinicaltrials), immediate access to the most current list of leukemia, lymphoma, myeloma and related blood cancer clinical trials currently underway.  The service gives patients and caregivers greater ability to explore cancer clinical trials as a potential treatment option at time of diagnosis and throughout the treatment process.]]></description>
  </item>
  <item>
  <title>Broken DNA Must Find Right Partners Quickly Amid Repairs</title>
  <pubDate>Thu, 24 Jul 2008 12:30:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=525022&amp;cat_id=140</link>
  <description><![CDATA[Just as square dance partners join hands at a particular point in the music, so broken pieces of DNA in our cells reunite as they are repaired]]></description>
  </item>
  <item>
  <title>Osteonecrosis Uncommon in Childhood Cancer Survivors</title>
  <pubDate>Wed, 16 Jul 2008 11:06:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523799&amp;cat_id=140</link>
  <description><![CDATA[Although osteonecrosis is rare in adult survivors of childhood cancer, they appear to be at significantly increased risk compared to their siblings, according to North American researchers.]]></description>
  </item>
  <item>
  <title>Thalidomide Continues to Show Benefits against Myeloma</title>
  <pubDate>Mon, 14 Jul 2008 10:50:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523619&amp;cat_id=140</link>
  <description><![CDATA[Researchers exploring the benefits of the once-banned drug thalidomide for patients with myeloma have learned a lesson that's as true to life as it is to science: Don't judge results too early.]]></description>
  </item>
  <item>
  <title>Lenalidomide Active in Heavily Pretreated Leukemia</title>
  <pubDate>Mon, 14 Jul 2008 10:48:06 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523617&amp;cat_id=140</link>
  <description><![CDATA[Lenalidomide can induce complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia (CLL), according to Houston-based researchers.]]></description>
  </item>
  <item>
  <title>Researcher Develops Method for Early Detection of Leukemia Relapse</title>
  <pubDate>Fri, 11 Jul 2008 16:00:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523498&amp;cat_id=140</link>
  <description><![CDATA[Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.]]></description>
  </item>
  <item>
  <title>Cancer Care Unaffected by Doctor Reimbursement Changes: Study</title>
  <pubDate>Thu, 10 Jul 2008 15:28:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523404&amp;cat_id=140</link>
  <description><![CDATA[Chemotherapy patients have not lost access to care despite federal legislation that has reduced reimbursements to their doctors in recent years, a new report finds.]]></description>
  </item>
  <item>
  <title>Mantle Cell Lymphoma on the Rise</title>
  <pubDate>Tue, 08 Jul 2008 10:13:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=523025&amp;cat_id=140</link>
  <description><![CDATA[A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma, is on the rise.]]></description>
  </item>
  <item>
  <title>Pegylated Liposomal Doxorubicin Effective in Hard-to-Treat Cutaneous T-Cell Lymphoma</title>
  <pubDate>Mon, 07 Jul 2008 13:06:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=522910&amp;cat_id=140</link>
  <description><![CDATA[Pegylated liposomal doxorubicin (Caelyx; Schering-Plough) is an effective therapy for advanced or refractory cutaneous T-cell lymphoma (CTCL), results of a study confirm.]]></description>
  </item>
  <item>
  <title>Talk to Your Doctor about Alternative Therapies: Feds</title>
  <pubDate>Thu, 03 Jul 2008 09:58:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=522678&amp;cat_id=140</link>
  <description><![CDATA[The federal government has a new message for people 50 and older who use complementary and alternative therapies, and their physicians too: do ask, and do tell.]]></description>
  </item>
  <item>
  <title>Combination Therapy: Real Advance for Patients with Follicular Lymphoma</title>
  <pubDate>Mon, 30 Jun 2008 13:38:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=522217&amp;cat_id=140</link>
  <description><![CDATA[Optimized biological treatment, which combines advanced antibody therapy plus chemotherapy, offers a promising approach to treating follicular lymphoma, according to a study.]]></description>
  </item>
  <item>
  <title>Insured Losing Access to Healthcare: U.S. Study</title>
  <pubDate>Mon, 30 Jun 2008 11:41:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=522167&amp;cat_id=140</link>
  <description><![CDATA[About 20 percent of the U.S. population delayed or was unable to get access to medical care when they needed it in 2007, up from 14 percent four years earlier, a study released on Thursday found.]]></description>
  </item>
  <item>
  <title>Important Factor in B-Cell Lymphoma Development Discovered</title>
  <pubDate>Tue, 24 Jun 2008 14:18:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=521661&amp;cat_id=140</link>
  <description><![CDATA[Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest-growing forms of cancer.]]></description>
  </item>
  <item>
  <title>One Gene May Be Key to Myeloma</title>
  <pubDate>Tue, 24 Jun 2008 14:15:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=521658&amp;cat_id=140</link>
  <description><![CDATA[Cancerous myeloma cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed.]]></description>
  </item>
  <item>
  <title>Leukemia Pill May Improve Stroke Treatment: Study</title>
  <pubDate>Mon, 23 Jun 2008 13:11:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=521489&amp;cat_id=140</link>
  <description><![CDATA[The drug Gleevec may reduce complications and boost the effectiveness of a treatment for the most common type of stroke, said an international team of researchers.]]></description>
  </item>
  <item>
  <title>Cancer as a Disease, Not a Death Sentence</title>
  <pubDate>Wed, 18 Jun 2008 13:13:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520843&amp;cat_id=140</link>
  <description><![CDATA[XX]]></description>
  </item>
  <item>
  <title>Individualized Therapies for Non-Hodgkin Lymphoma</title>
  <pubDate>Tue, 17 Jun 2008 14:35:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520763&amp;cat_id=140</link>
  <description><![CDATA[Positron emission tomography could be an important tool for identifying non-Hodgkin lymphoma patients who are likely to respond well to the first radioimmunotherapy treatment.]]></description>
  </item>
  <item>
  <title>High-Dose Imatinib for Chronic Myeloid Leukemia</title>
  <pubDate>Tue, 17 Jun 2008 14:25:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520756&amp;cat_id=140</link>
  <description><![CDATA[patients with chronic myeloid leukemia, front-line high-dose imatinib (Gleevec®) showed a rapid response and a trend toward a higher major molecular response at 12 months, although the improvement was not statistically significant compared with the standard 400 mg dose, study.]]></description>
  </item>
  <item>
  <title>Therapeutic Potential of Cord Blood Stem Cell Enhanced with New Technology</title>
  <pubDate>Thu, 12 Jun 2008 11:13:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520305&amp;cat_id=140</link>
  <description><![CDATA[A CD26 inhibitor increases the efficiency and responsiveness of umbilical cord blood for bone marrow transplants and may improve care for blood cancer patients according to research.]]></description>
  </item>
  <item>
  <title>Drug Effective against Follicular Lymphoma in Clinical Trial</title>
  <pubDate>Mon, 09 Jun 2008 15:25:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520037&amp;cat_id=140</link>
  <description><![CDATA[The Cancer and Leukemia Group B today announced data from a Phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab.]]></description>
  </item>
  <item>
  <title>Blood Cancer Drug Shows Promise against Lupus</title>
  <pubDate>Mon, 09 Jun 2008 15:21:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=520035&amp;cat_id=140</link>
  <description><![CDATA[drug used to treat multiple myeloma may also be a treatment for the chronic autoimmune disease lupus, German researchers report.]]></description>
  </item>
  <item>
  <title>Researchers Creating, Testing New Ways to Fight AML</title>
  <pubDate>Mon, 02 Jun 2008 15:38:11 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=519509&amp;cat_id=140</link>
  <description><![CDATA[The need for discovery of novel pathways to effectively eradicate leukemia-initiating cells in acute myeloid leukemia (AML) is essential for improving cure rates and reducing short- and long-term toxicities for these patients, according to presenters at the "Progress and Challenges in Pediatric Acute Myeloid Leukemia" Education Session held Friday. The session focused on targeting and outlining what is possible now and what may be possible in the future, said session Chair and Speaker Robert John Arceci, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.]]></description>
  </item>
  <item>
  <title>Antioxidants May Compromise Cancer Therapy</title>
  <pubDate>Wed, 28 May 2008 12:35:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=519106&amp;cat_id=140</link>
  <description><![CDATA[A review of randomized trial data suggests that cancer patients should avoid the routine use of antioxidant supplements as they may diminish the efficacy of chemotherapy and radiation.]]></description>
  </item>
  <item>
  <title>Heart Risks High in Childhood Cancer Survivors</title>
  <pubDate>Tue, 27 May 2008 13:54:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=519034&amp;cat_id=140</link>
  <description><![CDATA[Children who survive cancer while they are young are five to 10 times more likely than their healthy siblings to develop heart disease, U.S. researchers said on Thursday. The finding comes from a study of more than 14,000 survivors of childhood cancers, and suggests that cancer survivors and their doctors need to be vigilant about heart risks.]]></description>
  </item>
  <item>
  <title>Thalidomide Plus Dexamethasone: Improved Primary Myeloma Therapy</title>
  <pubDate>Thu, 22 May 2008 09:37:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=518775&amp;cat_id=140</link>
  <description><![CDATA[For initial therapy of multiple myeloma, combination treatment with thalidomide and dexamethasone, provides better results than those obtained with dexamethasone alone, researchers report in the May 1st issue of the Journal of Clinical oncology.]]></description>
  </item>
  <item>
  <title>Adding Epratuzumab to Standard Chemotherapy Promising for Lymphoma</title>
  <pubDate>Mon, 19 May 2008 14:15:42 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=518501&amp;cat_id=140</link>
  <description><![CDATA[Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers.]]></description>
  </item>
  <item>
  <title>Arsenic-Based Therapy Shown to Help Eradicate Leukemia-Initiating Cells</title>
  <pubDate>Mon, 12 May 2008 13:59:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=517882&amp;cat_id=140</link>
  <description><![CDATA[XX]]></description>
  </item>
  <item>
  <title>Immunologic Recovery Seen after Chemotherapy for AIDS-Related NHL</title>
  <pubDate>Mon, 12 May 2008 10:45:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=517840&amp;cat_id=140</link>
  <description><![CDATA[Patients who have undergone chemotherapy for AIDS-related non-Hodgkin's lymphoma (NHL) along with concomitant highly active antiretroviral therapy (HAART) do not experience prolonged suppression of immune function, according to UK researchers.]]></description>
  </item>
  <item>
  <title>Lenalidomide Raises Clot Risk in Multiple Myeloma Patients</title>
  <pubDate>Fri, 09 May 2008 09:40:19 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=517661&amp;cat_id=140</link>
  <description><![CDATA[Thromboembolic events are increased in patients undergoing lenalidomide-based therapy for multiple myeloma, US and Italian researchers report. Aspirin prophylaxis appears to reduce this risk.]]></description>
  </item>
  <item>
  <title>Genetic Changes May Dictate Course of Acute Myeloid Leukemia</title>
  <pubDate>Fri, 02 May 2008 10:53:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=517007&amp;cat_id=140</link>
  <description><![CDATA[Breakthroughs in understanding the extremely fine genetic underpinnings of acute myeloid leukemia may allow doctors to quickly decide which existing therapies will most benefit individual patients.]]></description>
  </item>
  <item>
  <title>Stored Ovarian Tissue Needs Testing Before Re-Implantation</title>
  <pubDate>Mon, 28 Apr 2008 12:45:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=516637&amp;cat_id=140</link>
  <description><![CDATA[Cancer can return in patients who have been successfully treated if ovarian or testicular tissue they had stored in hope of regaining fertility is transplanted back into their bodies without it being adequately checked for cancer cells, according to a new report.]]></description>
  </item>
  <item>
  <title>Co-Payments for Expensive Drugs Soar</title>
  <pubDate>Mon, 14 Apr 2008 13:49:47 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=514838&amp;cat_id=140</link>
  <description><![CDATA[Health insurance companies are rapidly adopting a new pricing system for very expensive drugs, asking patients to pay hundreds and even thousands of dollars for prescriptions for medications that may save their lives or slow the progress of serious diseases.]]></description>
  </item>
  <item>
  <title>Smoking and Heavy Drinking Affect NHL Survival</title>
  <pubDate>Mon, 14 Apr 2008 11:46:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=514818&amp;cat_id=140</link>
  <description><![CDATA[The results of a study published in the April issue of the International Journal of Cancer suggest that tobacco smoking and moderate-to-high alcohol consumption negatively affect the survival of patients with non-Hodgkin lymphoma (NHL).]]></description>
  </item>
  <item>
  <title>Cells on Path to Becoming Mature T-cells More Flexible than Commonly Thought</title>
  <pubDate>Thu, 10 Apr 2008 11:55:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=514096&amp;cat_id=140</link>
  <description><![CDATA[Contrary to the currently accepted model of T-cell development, researchers at the University of Pennsylvania School of Medicine have found that juvenile cells on their way to becoming mature immune cells can develop into either T cells or other blood-cell types.]]></description>
  </item>
  <item>
  <title>Family Cancer History Boosts Risk for Hodgkin Lymphoma Survivors</title>
  <pubDate>Tue, 01 Apr 2008 09:59:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=512346&amp;cat_id=140</link>
  <description><![CDATA[People who survive Hodgkin's lymphoma (HL) but have a family history of cancer are at greater risk for a second primary malignancy, according to Swedish researchers.]]></description>
  </item>
  <item>
  <title>Researchers Discover Way to Enhance Stem Cell Growth</title>
  <pubDate>Tue, 25 Mar 2008 12:31:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=511469&amp;cat_id=140</link>
  <description><![CDATA[Researchers have discovered a way to dramatically enhance the growth of stem cells from umbilical cord blood after transplantation.]]></description>
  </item>
  <item>
  <title>New Approach to Help Control Drug Resistance in Leukemia Identified</title>
  <pubDate>Tue, 25 Mar 2008 12:25:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=511464&amp;cat_id=140</link>
  <description><![CDATA[Researchers from Oregon Health & Science University Cancer Institute have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).]]></description>
  </item>
  <item>
  <title>EU Body Warns against Velcade Use in Some Patients</title>
  <pubDate>Mon, 24 Mar 2008 10:05:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=511164&amp;cat_id=140</link>
  <description><![CDATA[The European Medicines Agency has recommended that Millennium Pharmaceuticals Inc's cancer drug Velcade (bortezomib) should not be used in patients with certain severe pulmonary or heart problems.]]></description>
  </item>
  <item>
  <title>EBV Load Predicts Post-Transplant Lymphoproliferative Disease</title>
  <pubDate>Mon, 24 Mar 2008 10:03:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=511162&amp;cat_id=140</link>
  <description><![CDATA[Monitoring the level of Epstein-Barr virus (EBV) after hematopoietic stem cell transplantation (HSCT) allows early intervention in post-transplant lymphoproliferative disease, according to a report in the March issue of the Journal of Medical Virology.]]></description>
  </item>
  <item>
  <title>Treanda Approved for CLL Patients</title>
  <pubDate>Fri, 21 Mar 2008 08:59:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=511018&amp;cat_id=140</link>
  <description><![CDATA[On March 20, 2008, the Food and Drug Administration (FDA) approved bendamustine hydrochloride (TREANDA®, Cephalon, Inc.), an intravenously administered alkylating agent, for the treatment of patients with chronic lymphocytic leukemia (CLL).]]></description>
  </item>
  <item>
  <title>Dexrazoxane Not Linked with Secondary Cancers in Children with ALL</title>
  <pubDate>Thu, 20 Mar 2008 10:14:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=510705&amp;cat_id=140</link>
  <description><![CDATA[Dexrazoxane, which is used to prevent anthracycline-induced myocardial toxicity, does not appear to increase the risk of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia (ALL), according to a paper in the March 1 issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Lymphoma Patients Benefit from Combined PET-CT Scanning, Study Suggests</title>
  <pubDate>Mon, 17 Mar 2008 12:42:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509898&amp;cat_id=140</link>
  <description><![CDATA[Combined positron emission tomography (PET) and computed tomography (CT) imaging of lymphoma patients is a more effective method to evaluate response to radiation therapy and may help patients avoid unnecessary follow-up treatments.]]></description>
  </item>
  <item>
  <title>Combination Therapy Effective against Multiple Myeloma</title>
  <pubDate>Fri, 14 Mar 2008 13:34:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509725&amp;cat_id=140</link>
  <description><![CDATA[Treatment with a combination of clarithromycin, lenalidomide and dexamethasone is successful in most patients with newly diagnosed symptomatic multiple myeloma, according to New York-based researchers.]]></description>
  </item>
  <item>
  <title>Follicular NHL Responds Well to Radioimmunotherapy after Chemo</title>
  <pubDate>Fri, 14 Mar 2008 13:33:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509723&amp;cat_id=140</link>
  <description><![CDATA[In patients with advanced follicular non-Hodgkin's lymphoma who have not received previous treatment, radioimmunotherapy with Y-90-ibritumomab tiuxetan (Zevalin) improves the response to initial chemotherapy, according to results of a phase II trial in Italy.]]></description>
  </item>
  <item>
  <title>World-Renowned Researcher Brian Druker Shares the Latest News on Chronic Myelogenous Leukemia</title>
  <pubDate>Tue, 11 Mar 2008 14:17:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509033&amp;cat_id=140</link>
  <description><![CDATA[Oncologist Brian Druker, M.D., whose groundbreaking research has revolutionized treatment of cancer, will present the latest information about chronic myelogenous leukemia (CML) during a free telephone education program sponsored by The Leukemia & Lymphoma Society (LLS) through an unrestricted educational grant from Novartis Oncology.]]></description>
  </item>
  <item>
  <title>LLS Provides Patients with the Latest Information on Myeloma</title>
  <pubDate>Tue, 11 Mar 2008 14:16:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509031&amp;cat_id=140</link>
  <description><![CDATA[Myeloma patients can learn about myeloma treatment  and stem cell transplantation during a free telephone education workshop sponsored by The Leukemia & Lymphoma Society and led by myeloma expert Edward Stadtmauer, M.D., of  the University of Pennsylvania.]]></description>
  </item>
  <item>
  <title>Non-Hodgkin Patients Living Longer: Study</title>
  <pubDate>Tue, 11 Mar 2008 10:13:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=509005&amp;cat_id=140</link>
  <description><![CDATA[Improved treatments for non-Hodgkin's lymphoma helped patients live longer in the United States, researchers said on Monday.]]></description>
  </item>
  <item>
  <title>Researchers ID Promising New Cancer Drug</title>
  <pubDate>Tue, 04 Mar 2008 10:21:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=507666&amp;cat_id=140</link>
  <description><![CDATA[Researchers at the University of Michigan Comprehensive Cancer Center have designed a small molecule that may be highly effective against many cancers.]]></description>
  </item>
  <item>
  <title>Expressive Writing May Aid Cancer Patients</title>
  <pubDate>Tue, 04 Mar 2008 09:14:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=507660&amp;cat_id=140</link>
  <description><![CDATA[Writing about the experience of dealing with cancer may help boost some patients' well-being, a new study suggests.]]></description>
  </item>
  <item>
  <title>Sexual Function Does Not Fully Recover after Cell Transplantation</title>
  <pubDate>Tue, 04 Mar 2008 09:13:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=507658&amp;cat_id=140</link>
  <description><![CDATA[New research indicates that sexual dysfunction is often still apparent many years after a cancer patient has undergone hematopoietic cell transplantation (HCT).]]></description>
  </item>
  <item>
  <title>Imatinib Effective Over Long Term in Refractory Leukemia</title>
  <pubDate>Tue, 26 Feb 2008 08:27:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=506593&amp;cat_id=140</link>
  <description><![CDATA[Imatinib mesylate therapy shows lasting safety and efficacy in chronic-phase chronic myeloid leukemia (CML) patients in whom interferon-alpha treatment has failed.]]></description>
  </item>
  <item>
  <title>Eliminating Infection at Diagnosis of Slow-Growing NHL May Be Important Treatment Step</title>
  <pubDate>Mon, 25 Feb 2008 12:45:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=506484&amp;cat_id=140</link>
  <description><![CDATA[Individuals with advanced non-Hodgkin lymphoma (NHL) who also have certain infections at diagnosis may be able to delay treatment for NHL if their infection is treated first.]]></description>
  </item>
  <item>
  <title>Lymphopenia, Young Age Increases RSV Risk in Children with Cancer</title>
  <pubDate>Thu, 21 Feb 2008 11:09:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=506099&amp;cat_id=140</link>
  <description><![CDATA[Pediatric cancer patients younger than 2 years of age and those with profound lymphopenia are at highest risk for respiratory syncytial virus (RSV)-related lower respiratory tract infection and death, clinicians report in the February issue of Pediatrics.]]></description>
  </item>
  <item>
  <title>GnRH Agonist Reduces Chemotherapy-Induced Ovarian Failure</title>
  <pubDate>Thu, 21 Feb 2008 11:08:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=506097&amp;cat_id=140</link>
  <description><![CDATA[In a study of women of reproductive age undergoing chemotherapy for Hodgkin's lymphoma, cotreatment with a gonadotrophin-releasing hormone (GnRH) agonist significantly reduced ovarian damage.]]></description>
  </item>
  <item>
  <title>Chemotherapy for Hodgkin Lymphoma Linked to Premature Menopause</title>
  <pubDate>Tue, 19 Feb 2008 11:01:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=505746&amp;cat_id=140</link>
  <description><![CDATA[Female survivors of Hodgkin lymphoma treated with chemotherapy, especially alkylating agents, are at increased risk for premature menopause compared to those treated with radiotherapy only, according to findings published in the January issue of Blood.]]></description>
  </item>
  <item>
  <title>Comorbidities Affect Benefit of Conditioning Intensity for Stem Cell Transplants</title>
  <pubDate>Fri, 15 Feb 2008 10:08:17 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=505578&amp;cat_id=140</link>
  <description><![CDATA[Among patients with lymphoma and chronic lymphocytic leukemia undergoing allogeneic hematopoietic cell transplantation (HCT), those with comorbidities fare better with reduced intensity conditioning regimens, according to Seattle-based researchers.]]></description>
  </item>
  <item>
  <title>Tobacco and Alcohol May Decrease Survival for Non-Hodgkin Lymphoma Patients</title>
  <pubDate>Wed, 13 Feb 2008 13:58:06 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=505247&amp;cat_id=140</link>
  <description><![CDATA[Tobacco and Alcohol may Decrease Survival for Non-Hodgkin's Lymphoma Patients]]></description>
  </item>
  <item>
  <title>Gene Therapy Protocol Activates Immune System in Patients with Leukemia, Study Shows</title>
  <pubDate>Tue, 12 Feb 2008 12:00:32 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=505094&amp;cat_id=140</link>
  <description><![CDATA[A research team reports that patients with chronic lymphocytic leukemia (CLL) who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells. Read more.]]></description>
  </item>
  <item>
  <title>Medicare Chief Stands by Anemia Drug Decision</title>
  <pubDate>Mon, 11 Feb 2008 10:49:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=504904&amp;cat_id=140</link>
  <description><![CDATA[senior Medicare official said the case for cutting the use of controversial anemia drugs sold by Amgen Inc and Johnson & Johnson has become stronger since the agency decided last year to cut payments for their use in cancer patients.]]></description>
  </item>
  <item>
  <title>Male Patients with Hodgkin Lymphoma Face High Risk of Infertility</title>
  <pubDate>Tue, 05 Feb 2008 14:52:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=504260&amp;cat_id=140</link>
  <description><![CDATA[The majority of male patients treated for advanced Hodgkin lymphoma (HL) with the BEACOPP chemotherapy protocol become infertile as a result, though most already have impaired semen quality before treatment, according to the most comprehensive analysis of such patients to date. A small percentage of patients recover fertility between 1.5 and nearly 7 years after the end of therapy.]]></description>
  </item>
  <item>
  <title>High-Dose Methotrexate Effective Treatment for Primary CNS Lymphoma</title>
  <pubDate>Wed, 30 Jan 2008 14:14:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=503633&amp;cat_id=140</link>
  <description><![CDATA[Treatment with high-dose methotrexate leads to complete response in a substantial proportion of patients with primary CNS lymphoma, according to long-term follow-up of a phase II trial.]]></description>
  </item>
  <item>
  <title>Clinical Trial Access More Limited for Teen Cancer Patients</title>
  <pubDate>Fri, 25 Jan 2008 10:04:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=502946&amp;cat_id=140</link>
  <description><![CDATA[Adolescents and young adults with cancer appear to have less access to clinical trials and, therefore, the latest treatments, than their younger counterparts, according to a report in the December issue of the Journal of Pediatric Hematology/Oncology.]]></description>
  </item>
  <item>
  <title>New Guidelines Seek to Improve Palliative Care at End of Life</title>
  <pubDate>Tue, 22 Jan 2008 10:11:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=502582&amp;cat_id=140</link>
  <description><![CDATA[The American College of Physicians released guidelines on Monday that focus on improving the recognition and palliative care of pain, dyspnea, and depression -- the most common symptoms seen with a serious illness at the end of life.]]></description>
  </item>
  <item>
  <title>Second-Cancer Risk from Hodgkin Therapy Seen Reduced Substantially</title>
  <pubDate>Thu, 10 Jan 2008 09:02:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=501403&amp;cat_id=140</link>
  <description><![CDATA[Contemporary radiation therapy for Hodgkin lymphoma is expected to reduce the rate of second cancers substantially, although the risk varies considerably between individuals, according to a new report in Cancer for December 1.]]></description>
  </item>
  <item>
  <title>Study: Gentler Chemotherapy Before Stem Cell Transplant Causes Long-Term Remission of Follicular Lymphoma</title>
  <pubDate>Fri, 04 Jan 2008 11:14:17 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500904&amp;cat_id=140</link>
  <description><![CDATA[Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report.]]></description>
  </item>
  <item>
  <title>Oral Bisphosphonates May Cut Risk of Jaw Necrosis</title>
  <pubDate>Fri, 04 Jan 2008 10:49:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500900&amp;cat_id=140</link>
  <description><![CDATA[A report in the Journal of the American Dental Association for January clarifies the risk of jaw osteonecrosis associated with bisphosphonates. Intravenous bisphosphonates strongly increase the risk of adverse jaw outcomes, but oral bisphosphonates tend to decrease the risk, the research shows.]]></description>
  </item>
  <item>
  <title>Radiotherapy Suitable for Most Primary Cutaneous B-Cell Lymphomas</title>
  <pubDate>Thu, 03 Jan 2008 10:45:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500769&amp;cat_id=140</link>
  <description><![CDATA[Radiotherapy is appropriate for most patients with primary cutaneous B-cell lymphomas (CBCL), according to a recent Dutch study, but more aggressive treatment is needed in patients presenting with lesions on the leg.]]></description>
  </item>
  <item>
  <title>PET/CT Improves Evaluation of Pediatric Cancers</title>
  <pubDate>Thu, 03 Jan 2008 10:44:52 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500767&amp;cat_id=140</link>
  <description><![CDATA[In children with non-CNS malignancies, fluorodeoxyglucose (FDG) PET combined with CT in a single examination shows significantly better diagnostic performance than does conventional imaging, such as contrast CT or MRI, researchers report in the December issue of the Journal of Nuclear Medicine.]]></description>
  </item>
  <item>
  <title>Gleevec Delivers More Good News to Patients</title>
  <pubDate>Wed, 02 Jan 2008 15:28:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500722&amp;cat_id=140</link>
  <description><![CDATA[Gleevec®, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia.]]></description>
  </item>
  <item>
  <title>Alemtuzumab Safe, Effective First-Line Treatment for Chronic Lymphocytic Leukemia</title>
  <pubDate>Wed, 02 Jan 2008 13:25:52 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500598&amp;cat_id=140</link>
  <description><![CDATA[Alemtuzumab is superior to chlorambucil as first-line treatment for patients with chronic lymphocytic leukemia (CLL), according to results of a study published in the December issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Scaled-Down Chemo Regimen Seen Effective for AML in Down Syndrome</title>
  <pubDate>Wed, 02 Jan 2008 13:23:47 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500596&amp;cat_id=140</link>
  <description><![CDATA[A less intensive chemotherapeutic regimen designed specifically for treating acute myeloid leukemia (AML) in patients with Down syndrome (DS) yields excellent outcomes, Japanese researchers have found.]]></description>
  </item>
  <item>
  <title>New Program Offers Hope of Longer Survival for Myeloma Patients</title>
  <pubDate>Wed, 02 Jan 2008 09:39:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=500562&amp;cat_id=140</link>
  <description><![CDATA[A new program at Huntsman Cancer Institute, University of Utah, is now providing another treatment option that offers hope to multiple myeloma patients - a chance to live 10 or more years following diagnosis.]]></description>
  </item>
  <item>
  <title>Study: Insured Cancer Patients Do Better</title>
  <pubDate>Thu, 20 Dec 2007 11:53:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=499744&amp;cat_id=140</link>
  <description><![CDATA[Uninsured cancer patients are nearly twice as likely to die within five years as those with private coverage, according to the first national study of its kind and one that sheds light on troubling healthcare obstacles.]]></description>
  </item>
  <item>
  <title>Mortality Remains Elevated Years after Allogeneic Hematopoietic Cell Transplantation</title>
  <pubDate>Wed, 19 Dec 2007 10:53:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=499528&amp;cat_id=140</link>
  <description><![CDATA[Fifteen years after allogeneic hematopoietic cell transplantation (HCT), mortality rates among survivors are significantly higher than in the general population, according to a report in the November 15th issue Blood.]]></description>
  </item>
  <item>
  <title>Bosutinib Safe, Effective for Chronic Myelogenous Leukemia</title>
  <pubDate>Thu, 13 Dec 2007 13:49:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498995&amp;cat_id=140</link>
  <description><![CDATA[A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported.]]></description>
  </item>
  <item>
  <title>Investigational Agent Eliminates Resistance in CML</title>
  <pubDate>Thu, 13 Dec 2007 11:05:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498962&amp;cat_id=140</link>
  <description><![CDATA[A new Abl kinase inhibitor that eliminates resistance to nilotinib and dasatinib in the treatment of chronic myeloid leukemia (CML) in mice and in human cell lines was described this week at the 49th annual meeting of the American Society of Hematology in Atlanta, Georgia.]]></description>
  </item>
  <item>
  <title>New CLL Drug Appears Effective</title>
  <pubDate>Thu, 13 Dec 2007 09:31:11 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498940&amp;cat_id=140</link>
  <description><![CDATA[Cephalon Inc's experimental cancer drug Treanda was significantly more effective than a common chemotherapy agent in helping patients with chronic lymphocytic leukemia (CLL) who had not received prior treatment achieve remission, according to a late-stage study.]]></description>
  </item>
  <item>
  <title>Three-Drug Combination Extremely Promising As First-Line Therapy for Multiple Myeloma</title>
  <pubDate>Wed, 12 Dec 2007 12:56:12 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498825&amp;cat_id=140</link>
  <description><![CDATA[A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma.]]></description>
  </item>
  <item>
  <title>Novartis Says Tasigna Effective in Early Leukemia</title>
  <pubDate>Tue, 11 Dec 2007 11:01:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498667&amp;cat_id=140</link>
  <description><![CDATA[Novartis's cancer drug Tasigna (nilotinib) is effective as a first-line treatment for patients with newly diagnosed chronic myeloid leukaemia (CML), according to data presented on Sunday.]]></description>
  </item>
  <item>
  <title>Gentler Chemo Helps Patients Survive Lymphoma</title>
  <pubDate>Tue, 11 Dec 2007 11:00:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498665&amp;cat_id=140</link>
  <description><![CDATA[A gentler chemotherapy regimen may help some lymphoma patients better tolerate and benefit from bone marrow transplants, and the combination could even cure them, U.S. doctors reported on Monday.]]></description>
  </item>
  <item>
  <title>Investigational Drug Treanda Effective in Non-Hodgkin Lymphoma</title>
  <pubDate>Tue, 11 Dec 2007 10:59:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498663&amp;cat_id=140</link>
  <description><![CDATA[Cephalon Inc's experimental drug Treanda (bendamustine) appears to be effective in patients with non-Hodgkin's lymphoma (NHL) that had progressed during or following treatment with Rituxan (rituximab) in a late-stage study, the company and researchers said on Saturday.]]></description>
  </item>
  <item>
  <title>Anemia Drugs May Raise Blood Cancer Risk</title>
  <pubDate>Tue, 11 Dec 2007 10:57:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498661&amp;cat_id=140</link>
  <description><![CDATA[Erythropoiesis-stimulating drugs may increase the risk that patients with myelofibrosis will develop leukemia, U.S. researchers said on Monday.]]></description>
  </item>
  <item>
  <title>Reduced-Intensity Conditioning Safe with Stem Cell Transplant in CML</title>
  <pubDate>Tue, 11 Dec 2007 10:56:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498659&amp;cat_id=140</link>
  <description><![CDATA[A reduction in intensity of the conditioning regimen prior to hematopoietic stem cell transplantation does not significantly reduce overall survival and allows adequate disease control in chronic myelogenous leukemia (CML), researchers report in the November 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Revlimid Delays Myeloma Progression, According to Celgene</title>
  <pubDate>Tue, 11 Dec 2007 10:55:35 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498653&amp;cat_id=140</link>
  <description><![CDATA[Celgene Corp said on Sunday that its Revlimid (lenalidomide) in combination with dexamethasone improved survival in multiple myeloma than did dexamethasone alone.]]></description>
  </item>
  <item>
  <title>Novartis: Gleevec Stops Leukemia Progression</title>
  <pubDate>Tue, 11 Dec 2007 10:54:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498649&amp;cat_id=140</link>
  <description><![CDATA[Novartis's Glivec/Gleevec (imatinib) stopped cancer progression in all the patients between years 5 and 6 of a pivotal leukaemia trial, according to data presented on Sunday at the American Society of Hematology (ASH) meeting in Atlanta.]]></description>
  </item>
  <item>
  <title>Free Program on the Latest CML News</title>
  <pubDate>Tue, 11 Dec 2007 10:12:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498641&amp;cat_id=140</link>
  <description><![CDATA[Chronic myelogenous leukemia (CML) patients can learn about treatment options during a free telephone education workshop sponsored by Society and led by leukemia experts Eric Feldman, M.D. and Neil P. Shah, M.D., Ph.D.]]></description>
  </item>
  <item>
  <title>Society Shares the Latest Myeloma News</title>
  <pubDate>Tue, 11 Dec 2007 10:08:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498639&amp;cat_id=140</link>
  <description><![CDATA[Leading expert S. Vincent Rajkumar, M.D. will discuss novel treatment approaches for myeloma in a free telephone workshop entitled Emerging Therapies in Myeloma: News from the American Society of Hematology (ASH) Annual Meeting. The program is scheduled for Thursday, Jan. 10, 1 p.m. - 2:30 p.m. ET.]]></description>
  </item>
  <item>
  <title>U.S. Childhood Cancer Death Rate Declines Sharply</title>
  <pubDate>Mon, 10 Dec 2007 10:53:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=498388&amp;cat_id=140</link>
  <description><![CDATA[The cancer death rate for children in the United States has declined sharply -- down 20 percent from 1990 to 2004 -- thanks to better treatment of leukemia and other cancers, health officials said on Thursday.]]></description>
  </item>
  <item>
  <title>Positive Findings from Major Myeloma Study</title>
  <pubDate>Wed, 28 Nov 2007 12:00:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=497267&amp;cat_id=140</link>
  <description><![CDATA[Researchers from the Abramson Cancer Center of the University of Pennsylvania have announced findings from two large, international clinical trials showing unprecedented survival for patients with multiple myeloma. The findings show that with the oral drug lenalidomide, in combination with the steroid dexamethasone, patients significantly improved by all measures where previous treatments had failed.]]></description>
  </item>
  <item>
  <title>Researchers Transfer Immune Response to Myeloma Patient</title>
  <pubDate>Wed, 28 Nov 2007 11:56:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=497264&amp;cat_id=140</link>
  <description><![CDATA[Researchers at the University of Arkansas for Medical Sciences have for the first time transferred an immune response in a healthy individual to a patient with multiple myeloma, a cancer of the bone marrow, showing promise for cancer vaccination.]]></description>
  </item>
  <item>
  <title>Intensive Chemotherapy Prolongs Survival in Elderly AML Patients</title>
  <pubDate>Wed, 28 Nov 2007 10:50:47 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=497256&amp;cat_id=140</link>
  <description><![CDATA[Remission-induction chemotherapy improves the outcome of patients 60 years or older after a diagnosis of acute myeloid leukemia (AML), according to research conducted at the Cleveland Clinic in Ohio.]]></description>
  </item>
  <item>
  <title>Treatment with Lenalidomide Enhances Survival of Relapsed Multiple Myeloma</title>
  <pubDate>Mon, 26 Nov 2007 13:22:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=496771&amp;cat_id=140</link>
  <description><![CDATA[Adding lenalidomide, a structural analogue of thalidomide, to dexamethasone therapy can improve the overall and progression-free survival of patients with relapsed or refractory multiple myeloma, according to the results of two phase III trials appearing in The New England Journal of Medicine for November 22.]]></description>
  </item>
  <item>
  <title>Collectibles for a Cure</title>
  <pubDate>Mon, 26 Nov 2007 10:53:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=496719&amp;cat_id=140</link>
  <description><![CDATA[A high-end retailer of museum-quality collectibles is selling specially designed dishes and glassware to support The Leukemia & Lymphoma Society's research and patient services programs.]]></description>
  </item>
  <item>
  <title>Personalized Medicine Slowly Takes Shape</title>
  <pubDate>Fri, 16 Nov 2007 12:51:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=496091&amp;cat_id=140</link>
  <description><![CDATA[Personalized medicine - tailoring treatments to an individual's genetic profile - has been one of the main dreams of the gene revolution, but putting it into practice is proving tough.]]></description>
  </item>
  <item>
  <title>Chemo Plus Involved-Field Radiation Best for Early Hodgkin Lymphoma</title>
  <pubDate>Mon, 12 Nov 2007 10:06:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=495501&amp;cat_id=140</link>
  <description><![CDATA[Patients with early-stage Hodgkin's disease have better outcomes when chemotherapy is followed by involved-field radiotherapy rather than subtotal nodal radiotherapy, physicians in Europe report, which applies to patients with favorable or unfavorable characteristics.]]></description>
  </item>
  <item>
  <title>Probiotic Pills May Curb Chemo-Induced Diarrhea</title>
  <pubDate>Mon, 12 Nov 2007 10:04:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=495498&amp;cat_id=140</link>
  <description><![CDATA[In cancer patients, treatment with the probiotic Lactobacillus, a beneficial type of microbe, may reduce the frequency of severe diarrhea and abdominal pain that often comes with 5-fluorouracil (5-FU)-based chemotherapy, according to results of a randomized study conducted in Finland.]]></description>
  </item>
  <item>
  <title>FDA Strengthens Warnings, Approves Other Safety Labeling Changes for Erythropoiesis-Stimulating Agents</title>
  <pubDate>Fri, 09 Nov 2007 09:35:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=495340&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia. These new statements address the risks that the drugs Aranesp, Epogen and Procrit pose to patients with cancer and patients with chronic kidney failure.]]></description>
  </item>
  <item>
  <title>Study Links Obesity, Cancer</title>
  <pubDate>Thu, 08 Nov 2007 15:52:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=495305&amp;cat_id=140</link>
  <description><![CDATA[One of the largest medical studies ever undertaken has confirmed what many public health officials already feared: Being overweight can give you cancer. On Tuesday, the Million Women Study in the United Kingdom found that overweight and obese women are at higher risk of blood cancers and other malignancies.]]></description>
  </item>
  <item>
  <title>Gleevec Proves Safe and Effective Over the Long Term</title>
  <pubDate>Thu, 08 Nov 2007 13:34:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=495259&amp;cat_id=140</link>
  <description><![CDATA[The drug imatinib mesylate, more commonly known as Gleevec®, proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood.]]></description>
  </item>
  <item>
  <title>Exercise, Counseling Fight Cancer-Related Fatigue</title>
  <pubDate>Mon, 05 Nov 2007 12:24:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=494993&amp;cat_id=140</link>
  <description><![CDATA[Both exercise therapy and psychological counseling might offer some relief from the fatigue that often plagues cancer patients, a new research review suggests.]]></description>
  </item>
  <item>
  <title>Tasigna Approved for CML Patients Resistant to Other Therapies</title>
  <pubDate>Tue, 30 Oct 2007 11:03:52 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=494429&amp;cat_id=140</link>
  <description><![CDATA[Tasigna (nilotinib) has been approved by the U.S. Food and Drug Administration to treat chronic myeloid leukemia (CML) in people who are resistant or intolerant to other therapies, according to maker Novartis AG.]]></description>
  </item>
  <item>
  <title>Cognitive Function Recovers after Stem Cell Transplant</title>
  <pubDate>Tue, 30 Oct 2007 11:01:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=494502&amp;cat_id=140</link>
  <description><![CDATA[Cancer patients appear to show negative changes in cognitive functioning associated with hematopoietic stem cell transplantation (HSCT), but values return to a normative level within a year.]]></description>
  </item>
  <item>
  <title>Lonafarnib May Enhance Effect of Imatinib in Refractory Leukemia</title>
  <pubDate>Mon, 29 Oct 2007 12:30:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=494284&amp;cat_id=140</link>
  <description><![CDATA[The addition of lonafarnib to therapy with imatinib mesylate appears to be well tolerated and modestly synergistic in many patients with chronic myeloid leukemia who have failed treatment with imatinib alone.]]></description>
  </item>
  <item>
  <title>Test Gives Insight into Prognosis in Patients with Plasma Cell Malignancies</title>
  <pubDate>Mon, 29 Oct 2007 12:26:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=494277&amp;cat_id=140</link>
  <description><![CDATA[A new Mayo Clinic study shows that a chromosome test called "FISH" is better than conventional methods in identifying chromosomal genetic abnormalities associated with plasma cell malignancies.]]></description>
  </item>
  <item>
  <title>Updated Guidelines Released on Epoetin and Darbepoetin Use in Cancer Patients</title>
  <pubDate>Tue, 23 Oct 2007 10:57:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=493845&amp;cat_id=140</link>
  <description><![CDATA[The American Society of Hematology and the American Society of Clinical Oncology released new guidelines on Monday addressing the use of erythropoiesis-stimulating agents (ESAs) for chemotherapy-related anemia in cancer patients.]]></description>
  </item>
  <item>
  <title>Lenalidomide Plus Dexamethasone Effective for Newly Diagnosed Multiple Myeloma</title>
  <pubDate>Mon, 22 Oct 2007 10:02:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=493820&amp;cat_id=140</link>
  <description><![CDATA[A combination of lenalidomide (Revlimid; Celgene) and dexamethasone results in partial or better response rates in more than 90% of patients with newly diagnosed multiple myeloma, a Mayo Clinic study shows.]]></description>
  </item>
  <item>
  <title>AIDS-Related Virus Reveals More Ways to Cause Cancer</title>
  <pubDate>Tue, 09 Oct 2007 11:52:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492831&amp;cat_id=140</link>
  <description><![CDATA[Researchers at the University of Pennsylvania School of Medicine have shed new light on how Kaposi's sarcoma-associated Herpes Virus (KSHV) subverts normal cell machinery to cause cancer.]]></description>
  </item>
  <item>
  <title>Treatment-Related AML and MDS Rates &#34;Acceptably Low&#34; after Radiotherapy for NHL</title>
  <pubDate>Fri, 05 Oct 2007 10:38:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492587&amp;cat_id=140</link>
  <description><![CDATA[Following radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma (NHL), the incidence of treatment-related acute myelogenous leukemia (t-AML) and myelodysplastic syndrome (t-MDS) is 2.5% after 5 years, researchers report.]]></description>
  </item>
  <item>
  <title>Thalidomide Improves Survival of Multiple Myeloma in Elderly Patients</title>
  <pubDate>Fri, 05 Oct 2007 10:37:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492585&amp;cat_id=140</link>
  <description><![CDATA[In elderly patients with multiple myeloma, adding thalidomide to melphalan plus prednisone (MP), the standard therapy for the disease, can significantly improve overall survival, according to a report in the October 6th issue of The Lancet.]]></description>
  </item>
  <item>
  <title>Daisies Lead Scientists Down Path to New Leukemia Drug</title>
  <pubDate>Fri, 05 Oct 2007 10:35:37 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492583&amp;cat_id=140</link>
  <description><![CDATA[A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal Blood.]]></description>
  </item>
  <item>
  <title>Society Offers Program on Acute Myelogenous Leukemia Treatments</title>
  <pubDate>Thu, 04 Oct 2007 10:40:11 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492516&amp;cat_id=140</link>
  <description><![CDATA[Patients with acute myelogenous leukemia (AML) can learn about treatment options during a free Society teleconference led by leukemia expert Jacob M. Rowe, M.D., of the Israel Institute of Technology.]]></description>
  </item>
  <item>
  <title>Society Presents Free October Program on Childhood Leukemia and Lymphoma</title>
  <pubDate>Thu, 04 Oct 2007 10:36:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492514&amp;cat_id=140</link>
  <description><![CDATA[Parents and caregivers of children with leukemia and lymphoma can learn about treatment options and clinical trials during a free telephone education workshop led by Barton A. Kamen, M.D., Ph.D., the Society's chief medical officer.]]></description>
  </item>
  <item>
  <title>Lifestyle Factors, Obesity Impact Lymphoma Risk</title>
  <pubDate>Tue, 02 Oct 2007 09:06:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492344&amp;cat_id=140</link>
  <description><![CDATA[Body size and patterns of smoking and drinking appear to modulate a person's risk of developing Hodgkin's and non-Hodgkin's lymphoma, a study shows.]]></description>
  </item>
  <item>
  <title>Common Pain Screening Test Often Inaccurate</title>
  <pubDate>Tue, 02 Oct 2007 09:05:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492342&amp;cat_id=140</link>
  <description><![CDATA[A pain screening method widely used in US primary care settings is doing a poor job of identifying patients with serious pain, a new study suggests.]]></description>
  </item>
  <item>
  <title>October Program Provides Patients with Latest Information on Myeloma</title>
  <pubDate>Wed, 26 Sep 2007 15:01:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=492000&amp;cat_id=140</link>
  <description><![CDATA[Myeloma patients can learn about managing side effects during a free Society telephone education workshop led by myeloma experts Melissa Alsina, M.D., and Kathy Daily, R.N., of H. Lee Moffitt Cancer & Research Institute.]]></description>
  </item>
  <item>
  <title>Zingo Offers Pain Relief During Child Injections</title>
  <pubDate>Mon, 24 Sep 2007 09:56:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=491585&amp;cat_id=140</link>
  <description><![CDATA[The pain-relieving drug Zingo (lidocaine hydrochloride) has been approved by the U.S. Food and Drug Administration for children who undergo IV insertions or blood draws.]]></description>
  </item>
  <item>
  <title>Cancer&#39;s Sandwich Generation: Young Adults</title>
  <pubDate>Fri, 21 Sep 2007 15:54:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=491528&amp;cat_id=140</link>
  <description><![CDATA[For young adults, cancer is often undiagnosed and untreated until it is too late.]]></description>
  </item>
  <item>
  <title>Bayer, Genzyme Get OK for Wider Use of Drug for CLL</title>
  <pubDate>Fri, 21 Sep 2007 10:11:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=491476&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved the use of leukemia drug Campath to newly diagnosed patients, Bayer and Genzyme Corp said on Thursday.]]></description>
  </item>
  <item>
  <title>How to Improve Patient Participation in Clinical Trials</title>
  <pubDate>Thu, 20 Sep 2007 12:18:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=491409&amp;cat_id=140</link>
  <description><![CDATA[Before a new treatment becomes available, researchers must recruit hundreds or thousands of patients to participate in clinical research trials. But finding these patients is often difficult.]]></description>
  </item>
  <item>
  <title>Society Encouraged by Promising Myeloma News</title>
  <pubDate>Tue, 18 Sep 2007 11:00:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=491196&amp;cat_id=140</link>
  <description><![CDATA[Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade® (bortezomib) showed that the patients treated on the Velcade arm did better.]]></description>
  </item>
  <item>
  <title>Stem Cells from Cord Blood Could Become the Standard</title>
  <pubDate>Tue, 11 Sep 2007 12:09:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=490565&amp;cat_id=140</link>
  <description><![CDATA[Today, stem cells from bone marrow are considered the ''gold standard'' for treating leukemia, many immunologists say. But that may be changing.]]></description>
  </item>
  <item>
  <title>Study Finds Heart Failure Rare among Leukemia Patients on Imatinib</title>
  <pubDate>Fri, 07 Sep 2007 11:35:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=490229&amp;cat_id=140</link>
  <description><![CDATA[Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at The University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.]]></description>
  </item>
  <item>
  <title>Society Hosts Workshop on Treatment Options for Chronic Myelogenous Leukemia</title>
  <pubDate>Fri, 07 Sep 2007 10:16:12 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=490224&amp;cat_id=140</link>
  <description><![CDATA[Jorge Cortes, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled CML: A Model in Cancer Therapy. The program is scheduled for Thursday, Sep. 20, 12 p.m. - 1 p.m. ET.]]></description>
  </item>
  <item>
  <title>First U.S. Clinical Trial Using T-Reg Cells from Cord Blood in Leukemia Treatment Begins</title>
  <pubDate>Thu, 06 Sep 2007 12:14:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=490186&amp;cat_id=140</link>
  <description><![CDATA[University of Minnesota researchers have initiated a ground-breaking clinical trial to determine the optimal dose and safety of T regulatory cells (T-regs) to decrease the risk of immune reactions common in patients undergoing blood and marrow transplantation.]]></description>
  </item>
  <item>
  <title>Teen Cancer Survivors Show Mood, Behavior Problems</title>
  <pubDate>Thu, 06 Sep 2007 11:30:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=490178&amp;cat_id=140</link>
  <description><![CDATA[Teenagers who've survived childhood cancers may be more likely than their siblings to be depressed or anxious, have attention problems or show antisocial behaviors, researchers report.]]></description>
  </item>
  <item>
  <title>Leukemia Therapy Can Impair &lt;br&gt;School Performance</title>
  <pubDate>Tue, 04 Sep 2007 10:23:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=489923&amp;cat_id=140</link>
  <description><![CDATA[Certain treatments may affect scholastic achievements in survivors of childhood leukemia, Finnish researchers report in the August 10th issue of the Journal of Clinical Oncology. However, many such children do not appear to be disadvantaged.]]></description>
  </item>
  <item>
  <title>Fertility Concerns Persist after Stem Cell Transplantation</title>
  <pubDate>Thu, 30 Aug 2007 10:57:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=489709&amp;cat_id=140</link>
  <description><![CDATA[Adult survivors of cancer who underwent myeloablative hematopoietic cell transplantation have long-term fertility concerns throughout ten years of follow-up, a study conducted at the University of Washington, Seattle, shows.]]></description>
  </item>
  <item>
  <title>The Society Provides Patients with the Latest Information on Non-Hodgkin Lymphoma</title>
  <pubDate>Thu, 30 Aug 2007 10:19:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=489702&amp;cat_id=140</link>
  <description><![CDATA[Non-Hodgkin lymphoma patients can learn about emerging treatment options during a free telephone education workshop sponsored by the Society and led by lymphoma expert Jonathan Friedberg, M.D., M.M.Sc., of the University of Rochester's Wilmot Cancer Center.]]></description>
  </item>
  <item>
  <title>Rituximab Negates PRDM1-Related Resistance in Lymphoma</title>
  <pubDate>Thu, 09 Aug 2007 11:29:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=487848&amp;cat_id=140</link>
  <description><![CDATA[Rituximab overcomes resistance to chemotherapy related to the expression of PRDM1 in patients with diffuse large B-cell lymphoma (DLBCL), according to findings published in the July 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Aggressive Therapy Best for Certain AML Patients</title>
  <pubDate>Thu, 02 Aug 2007 12:45:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=487003&amp;cat_id=140</link>
  <description><![CDATA[A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy.  More>]]></description>
  </item>
  <item>
  <title>Oseltamivir Prevents Influenza in Hematopoietic Stem Cell Transplant Recipients</title>
  <pubDate>Thu, 02 Aug 2007 10:22:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486995&amp;cat_id=140</link>
  <description><![CDATA[Oseltamivir prophylaxis safely prevents influenza in patients with hematopoietic stem cell transplants (HSCT), according to a report in the July 15th issue of Clinical Infectious Diseases.]]></description>
  </item>
  <item>
  <title>Harvard Researchers Identify Treatment Target in Hodgkin Lymphoma</title>
  <pubDate>Wed, 01 Aug 2007 12:06:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486837&amp;cat_id=140</link>
  <description><![CDATA[Harvard researchers report that they have identified a protein that could be a potentially significant target for future Hodgkin lymphoma therapies. To read more, including a comment by the Society's Deborah Banker, Ph.D., click here.]]></description>
  </item>
  <item>
  <title>Acyclovir Useful HSV Prophylaxis after Stem-Cell Transplant</title>
  <pubDate>Wed, 01 Aug 2007 10:12:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486826&amp;cat_id=140</link>
  <description><![CDATA[Long-term suppressive acyclovir therapy in hematopoietic stem-cell transplant (HCT) recipients can prevent the emergence of herpes simplex virus (HSV) disease, including acyclovir-resistant HSV disease, researchers report in the July 15th issue of the Journal of Infectious Diseases.]]></description>
  </item>
  <item>
  <title>Intensive Chemotherapy No Benefit in Some Elderly Leukemia Patients</title>
  <pubDate>Wed, 01 Aug 2007 10:11:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486824&amp;cat_id=140</link>
  <description><![CDATA[For patients 60 years old and older who have myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) with high-risk karyotypes, intensive chemotherapy does little to prolong survival and is not recommended, European researchers report.]]></description>
  </item>
  <item>
  <title>Medicare Tightens Reimbursement for Anemia Drugs</title>
  <pubDate>Tue, 31 Jul 2007 17:24:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486805&amp;cat_id=140</link>
  <description><![CDATA[The Centers for Medicare & Medicaid Services (CMS) issued final reimbursement rules on Monday that tighten usage and dosing allowances for a class of anemia drugs due to concerns over their safety and potential overuse.]]></description>
  </item>
  <item>
  <title>Many Americans Believe Unsubstantiated Claims About Cancer, Survey Finds</title>
  <pubDate>Fri, 27 Jul 2007 15:32:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486563&amp;cat_id=140</link>
  <description><![CDATA[A new study finds a surprising number of Americans believe scientifically unsubstantiated claims concerning cancer, and that population segments suffering the greatest burden of cancer are the most likely to be misinformed.]]></description>
  </item>
  <item>
  <title>White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications</title>
  <pubDate>Fri, 27 Jul 2007 14:26:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=486539&amp;cat_id=140</link>
  <description><![CDATA[Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels.]]></description>
  </item>
  <item>
  <title>Drug Combo Effective against Leukemia</title>
  <pubDate>Tue, 24 Jul 2007 14:57:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=485113&amp;cat_id=140</link>
  <description><![CDATA[Patients with the most common type of leukemia achieved better responses to treatment with two cancer-fighting drugs than one in a large international study.  More>]]></description>
  </item>
  <item>
  <title>Obesity Found to Be a Risk Factor for Multiple Myeloma</title>
  <pubDate>Tue, 24 Jul 2007 14:55:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=485111&amp;cat_id=140</link>
  <description><![CDATA[An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women's Hospital, Harvard Medical School and Harvard School of Public Health.]]></description>
  </item>
  <item>
  <title>Hybrid Protocol May Improve Treatment of Infant Leukemia</title>
  <pubDate>Tue, 24 Jul 2007 14:53:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=485109&amp;cat_id=140</link>
  <description><![CDATA[Use of a special hybrid treatment protocol appears to improve event-free survival (EFS) in infants with acute lymphoblastic leukemia (ALL), particularly those with a poor response to prednisone, new research suggests.]]></description>
  </item>
  <item>
  <title>Tipifarnib May Benefit Certain Patients with Refractory or Relapsed AML</title>
  <pubDate>Mon, 09 Jul 2007 11:26:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=483235&amp;cat_id=140</link>
  <description><![CDATA[The farnesyltransferase inhibitor (FTI) tipifarnib is effective in some patients with refractory or relapsed acute myeloid leukemia (AML), according to a report in the June 15th issue of Blood.]]></description>
  </item>
  <item>
  <title>Doctors Offer Fertility Hope to Cancer Children</title>
  <pubDate>Mon, 09 Jul 2007 11:25:19 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=483233&amp;cat_id=140</link>
  <description><![CDATA[Doctors have extracted, matured and frozen eggs from girls as young as five in a move that may allow children with cancer to become parents when they grow up, scientists said on Sunday.]]></description>
  </item>
  <item>
  <title>&#34;Modular&#34; Leukemia Drug Shows Promise in Early Testing</title>
  <pubDate>Fri, 29 Jun 2007 10:56:51 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=482352&amp;cat_id=140</link>
  <description><![CDATA[A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.  The agent represents a new class of agents called small modular immunopharmaceuticals. Read more.]]></description>
  </item>
  <item>
  <title>Society Shares the Latest News on Chronic Myelogenous Leukemia</title>
  <pubDate>Fri, 22 Jun 2007 15:06:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481669&amp;cat_id=140</link>
  <description><![CDATA[Neil Shah, M.D., Ph.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled The Latest on CML - Update from the American Society of Clinical Oncology (ASCO) Annual Meeting. The program is scheduled for Thursday, Jun. 28, 2007, 12 p.m. - 1:30 p.m. ET.]]></description>
  </item>
  <item>
  <title>Society Offers Program on Chronic Lymphocytic Leukemia</title>
  <pubDate>Fri, 22 Jun 2007 15:01:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481667&amp;cat_id=140</link>
  <description><![CDATA[John Byrd, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic lymphocytic leukemia (CLL) in a free telephone workshop entitled Current Progress in CLL Therapy and Clinical Trials. The program is scheduled for Tuesday, Jun. 26, 2007, 1 p.m. - 2 p.m. ET.]]></description>
  </item>
  <item>
  <title>Predictors of Multiple Myeloma Progression Identified</title>
  <pubDate>Thu, 21 Jun 2007 13:12:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481527&amp;cat_id=140</link>
  <description><![CDATA[The proportion of plasma cells in bone marrow and the serum monoclonal protein level at diagnosis influence the risk that smoldering (asymptomatic) multiple myeloma will progress to symptomatic disease, new research suggests.]]></description>
  </item>
  <item>
  <title>Drug Found in See-Through Fish May Aid Stem Cell Transplants</title>
  <pubDate>Thu, 21 Jun 2007 13:10:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481524&amp;cat_id=140</link>
  <description><![CDATA[A drug found by studying see-through fish might help leukemia patients by boosting the number of transplanted stem cells that make blood, Harvard University scientists said. The Society helped fund the study. Read more.]]></description>
  </item>
  <item>
  <title>Non-Hodgkin Lymphoma Guidelines Updated</title>
  <pubDate>Wed, 20 Jun 2007 15:04:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481434&amp;cat_id=140</link>
  <description><![CDATA[The National Comprehensive Cancer Network (NCCN) has updated its Non-Hodgkin Lymphoma (NHL) Guidelines, which are used to set standards of care in the United States. Read more.]]></description>
  </item>
  <item>
  <title>Chemoimmunotherapy Effective in Elderly with Chronic Lymphocytic Leukemia</title>
  <pubDate>Tue, 19 Jun 2007 09:51:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=481214&amp;cat_id=140</link>
  <description><![CDATA[Chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab (PCR) is effective in older patients with chronic lymphocytic leukemia (CLL), according to a report in the June 1st Cancer.]]></description>
  </item>
  <item>
  <title>Lymphoma Drug Bexxar Effective Over Long Term, Study Finds</title>
  <pubDate>Wed, 13 Jun 2007 15:53:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=479926&amp;cat_id=140</link>
  <description><![CDATA[Eight years after being treated with Bexxar®, a new drug for non-Hodgkin lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.]]></description>
  </item>
  <item>
  <title>Revlimid Data May Change How  Physicians Treat Myeloma</title>
  <pubDate>Mon, 11 Jun 2007 12:35:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=479692&amp;cat_id=140</link>
  <description><![CDATA[Findings from a Phase III study demonstrate the benefits of using Revlimid® (lenalidomide) with reduced doses of the steroid dexamethasone. Read more.]]></description>
  </item>
  <item>
  <title>Rapid Rituximab Infusion Practical in Lymphoma Patients</title>
  <pubDate>Mon, 11 Jun 2007 09:58:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=479674&amp;cat_id=140</link>
  <description><![CDATA[Rapid infusion of rituximab in combination with corticosteroids is well tolerated by patients with non-Hodgkin's lymphoma, according to Canadian researchers.]]></description>
  </item>
  <item>
  <title>Unrelated Cord Blood Transplants an Option for Children with Leukemia</title>
  <pubDate>Fri, 08 Jun 2007 12:53:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=479273&amp;cat_id=140</link>
  <description><![CDATA[In children with leukemia, transplantation of unrelated umbilical cord blood yields outcomes similar to transplantation of allele-matched bone marrow, suggest results of a large study.]]></description>
  </item>
  <item>
  <title>Anti-TNF Therapy Not Tied to Lymphoma in Rheumatoid Arthritis Patients</title>
  <pubDate>Fri, 08 Jun 2007 12:52:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=479269&amp;cat_id=140</link>
  <description><![CDATA[study involving more than 19,000 patients with rheumatoid arthritis (RA) indicates that there is no relationship between use of methotrexate and anti-tumor necrosis factor (anti-TNF) and the subsequent development of lymphoma.]]></description>
  </item>
  <item>
  <title>Anemia Drug Safety Debate Overblown: Doctors</title>
  <pubDate>Thu, 07 Jun 2007 16:25:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=478895&amp;cat_id=140</link>
  <description><![CDATA[Debate about the safety of a group of anemia drugs widely used in cancer patients should focus on a minority of patients who got the drugs for unapproved uses, doctors said on Sunday.]]></description>
  </item>
  <item>
  <title>Herb Shows Potential to Reduce Cancer-Related Fatigue</title>
  <pubDate>Wed, 06 Jun 2007 09:25:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477955&amp;cat_id=140</link>
  <description><![CDATA[American ginseng shows promise as a treatment for cancer-related fatigue, according to research at the Mayo Clinic. Read more.]]></description>
  </item>
  <item>
  <title>Promising Results with Epratuzumab and Chemotherapy in Children with ALL</title>
  <pubDate>Tue, 05 Jun 2007 16:08:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477856&amp;cat_id=140</link>
  <description><![CDATA[Immunomedics Inc. has announced that treatment with epratuzumab plus standard chemotherapy is feasible and well tolerated in children with B-precursor acute lymphoblastic leukemia (ALL), producing favorable early responses in the majority of patients.]]></description>
  </item>
  <item>
  <title>More Childhood Cancer Survivors Need Long-Term Follow-Up Care</title>
  <pubDate>Mon, 04 Jun 2007 11:42:32 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477320&amp;cat_id=140</link>
  <description><![CDATA[Results of a new study show that the majority of survivors of childhood cancer do not receive specialized long-term medical care, even though they are known to be at high risk for long-term health problems. Read more.]]></description>
  </item>
  <item>
  <title>Arsenic Compound Helps Patients with Rare Leukemia Live Longer</title>
  <pubDate>Mon, 04 Jun 2007 11:39:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477317&amp;cat_id=140</link>
  <description><![CDATA[Adding arsenic trioxide (Trisenox) to standard treatment significantly extends the lives of adults with newly diagnosed acute promyelocytic leukemia (APL), according to a new study. APL is a subtype of acute myeloid leukemia (AML) and accounts for about 1,500 cases in the United States each year. It is most often diagnosed in young and middle-age adults.]]></description>
  </item>
  <item>
  <title>New Drug Effective as First Treatment for Chronic Myeloid Leukemia</title>
  <pubDate>Mon, 04 Jun 2007 11:37:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477314&amp;cat_id=140</link>
  <description><![CDATA[Dasatinib (Sprycel®) is effective as an initial treatment for newly diagnosed patients with chronic phase (early stage) chronic myeloid leukemia, according to a Phase II clinical trial from The University of Texas M. D. Anderson Cancer Center in Houston. Read more.]]></description>
  </item>
  <item>
  <title>CLL Linked to Inherited Gene Mutation</title>
  <pubDate>Fri, 01 Jun 2007 14:50:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=477176&amp;cat_id=140</link>
  <description><![CDATA[A gene that dramatically increases the risk of adult chronic lymphocytic leukemia (CLL) has been identified.]]></description>
  </item>
  <item>
  <title>FDA Approves Doxorubicin/Bortezomib Combination for Myeloma</title>
  <pubDate>Wed, 23 May 2007 12:31:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=475764&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) has granted approval to doxorubicin HCl liposome injection for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.]]></description>
  </item>
  <item>
  <title>Cancer Not Spread through Blood Transfusions</title>
  <pubDate>Mon, 21 May 2007 11:57:50 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474779&amp;cat_id=140</link>
  <description><![CDATA[People who receive a blood transfusion from individuals with undiagnosed cancer are not at increased risk for developing the malignancy themselves, new research indicates.]]></description>
  </item>
  <item>
  <title>New Guidelines on the Role of Bisphosphonates in Multiple Myeloma</title>
  <pubDate>Mon, 21 May 2007 11:56:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474777&amp;cat_id=140</link>
  <description><![CDATA[The American Society of Clinical Oncology (ASCO) has developed updated guideline recommendations on the use of bisphosphonates, medications that help strengthen the bone, in people with multiple myeloma.]]></description>
  </item>
  <item>
  <title>Imatinib and Steroids Helpful in Elderly with Acute Lymphoblastic Leukemia</title>
  <pubDate>Mon, 21 May 2007 11:19:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474765&amp;cat_id=140</link>
  <description><![CDATA[Without additional chemotherapy, imatinib along with steroid treatment may induce complete remission and prolong survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia (ALL), Italian researchers report in the May 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Radiolabeled Monoclonal Antibody to CD20 Curbs Refractory Lymphoma</title>
  <pubDate>Fri, 18 May 2007 13:01:17 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474622&amp;cat_id=140</link>
  <description><![CDATA[Radiolabeled monoclonal antibody to CD20 curbs refractory lymphoma]]></description>
  </item>
  <item>
  <title>Enzastaurin Delays Progression in Diffuse Large B-Cell Lymphoma</title>
  <pubDate>Fri, 18 May 2007 09:58:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474538&amp;cat_id=140</link>
  <description><![CDATA[protein kinase C (PKC)-beta inhibitor enzastaurin prolongs freedom from progression in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a report in the May 1st issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Study Contradicts Belief that Psychotherapy Extends Cancer Patients&#39; Lives</title>
  <pubDate>Wed, 16 May 2007 10:29:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=474220&amp;cat_id=140</link>
  <description><![CDATA[Psychotherapy and support groups do not prolong the survival of cancer patients, according to a report in the May issue of the Psychological Bulletin.]]></description>
  </item>
  <item>
  <title>Lung Involvement in Cutaneous T-Cell Lymphoma a Poor Sign</title>
  <pubDate>Mon, 14 May 2007 11:01:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473850&amp;cat_id=140</link>
  <description><![CDATA[Pneumonia and lung involvement are relatively rare in patients with cutaneous T-cell lymphoma (CTCL), but are associated with poor survival, according to Texas-based researchers.]]></description>
  </item>
  <item>
  <title>High BMI Tied to Osteonecrosis in Childhood Leukemia</title>
  <pubDate>Thu, 10 May 2007 10:30:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473555&amp;cat_id=140</link>
  <description><![CDATA[A high body mass index (BMI) increases the risk for osteonecrosis in children with acute lymphoblastic leukemia (ALL), according to Finnish researchers.]]></description>
  </item>
  <item>
  <title>Erythropoietin Therapy Often Less than Optimal</title>
  <pubDate>Thu, 10 May 2007 09:30:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473540&amp;cat_id=140</link>
  <description><![CDATA[Nononcologic use of human recombinant erythropoietin (rHuEPO) therapy in hospitalized patients shows considerable room for improvement, investigators report.]]></description>
  </item>
  <item>
  <title>Chemotherapy with Rituximab Is Better for Indolent Lymphoma Patients</title>
  <pubDate>Thu, 10 May 2007 09:29:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473538&amp;cat_id=140</link>
  <description><![CDATA[Patients with indolent or mantle cell lymphoma have higher overall survival rates when given the antibody rituximab in addition to their standard chemotherapy, a combination called R-chemo.]]></description>
  </item>
  <item>
  <title>Family History of Blood Cancer Increases Non-Hodgkin Lymphoma Risk</title>
  <pubDate>Thu, 10 May 2007 09:27:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473536&amp;cat_id=140</link>
  <description><![CDATA[family history of non-Hodgkin lymphoma, Hodgkin lymphoma, or leukemia increases the risk of non-Hodgkin lymphoma, according to a report in the April 15th issue of Blood.]]></description>
  </item>
  <item>
  <title>Electromagnetic Fields Not Increasing Cancer Risk among Energy Workers Overall: Study</title>
  <pubDate>Thu, 10 May 2007 09:21:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473532&amp;cat_id=140</link>
  <description><![CDATA[Electromagnetic fields do not pose a health hazard to workers in the electrical energy supply industry, suggests a large study of 28,000 people.]]></description>
  </item>
  <item>
  <title>Workplace Cancers Cause 200,000 Deaths a Year: WHO</title>
  <pubDate>Thu, 10 May 2007 09:19:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=473524&amp;cat_id=140</link>
  <description><![CDATA[At least 200,000 people die every year from cancers related to their workplaces, mainly from inhaling asbestos fibers and second-hand tobacco smoke, the World Health Organisation (WHO) said on Friday.]]></description>
  </item>
  <item>
  <title>Combination Therapy with Tositumomab Aids Elderly Lymphoma Patients</title>
  <pubDate>Fri, 27 Apr 2007 12:40:35 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=472088&amp;cat_id=140</link>
  <description><![CDATA[Myeloablative anti-CD20 radioimmunotherapy and autologous hematopoietic stem-cell transplantation (ASCT) can provide safe and effective treatment for elderly patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.]]></description>
  </item>
  <item>
  <title>IV Pegaspargase Safe in Adults with ALL</title>
  <pubDate>Fri, 27 Apr 2007 12:39:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=472086&amp;cat_id=140</link>
  <description><![CDATA[Intravenous pegaspargase appears to be safe when used as a component of a remission-induction regimen in adults with newly diagnosed acute lymphoblastic leukemia (ALL), researchers report in the April 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Autografts or Allografts: the Primary Unanswered Question in Multiple Myeloma</title>
  <pubDate>Thu, 26 Apr 2007 16:04:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471989&amp;cat_id=140</link>
  <description><![CDATA[There is a higher risk of relapse with reduced-intensity conditioning (RIC) than myeloablative conditioning (MAC) prior to allogeneic stem cell transplantation in multiple myeloma, British researchers report. However, the overarching issue may be whether to perform allogenic or autologous transplants.]]></description>
  </item>
  <item>
  <title>Breastfeeding Can Cut Risk of Childhood Leukemia: Study Suggests</title>
  <pubDate>Mon, 23 Apr 2007 14:32:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471264&amp;cat_id=140</link>
  <description><![CDATA[According to the federal Agency for Healthcare Research and Quality, there is new evidence that breastfeeding decreases infants' and mothers' risk of having many short-term and chronic diseases, including childhood leukemia.]]></description>
  </item>
  <item>
  <title>Bortezomib Boosts Response in Refractory Myeloma</title>
  <pubDate>Mon, 23 Apr 2007 13:04:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471247&amp;cat_id=140</link>
  <description><![CDATA[Multiple myeloma treatment with melphalan, prednisone and thalidomide (MPT) appears to be improved with the addition of the proteasome inhibitor bortezomib, Italian researchers report in the April 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Knocking Out Survival Protein Could Aid Leukemia Treatment</title>
  <pubDate>Mon, 23 Apr 2007 13:03:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471245&amp;cat_id=140</link>
  <description><![CDATA[An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows. The findings suggest that a drug that can block this "survival protein" might on its own be an effective therapy.]]></description>
  </item>
  <item>
  <title>New Method Predicts Hip Joint Decay from Chemotherapy</title>
  <pubDate>Fri, 20 Apr 2007 15:57:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471116&amp;cat_id=140</link>
  <description><![CDATA[Investigators at St. Jude Children's Research Hospital say they have found the best way for predicting when patients will need future surgery to repair hip joints that have deteriorated because of pediatric leukemia or lymphoma treatment. The investigators found that if more than 30 percent of the head of the bone fitting into the hip socket is deteriorated, it is at high risk of collapsing and requiring reconstructive surgery within two years.]]></description>
  </item>
  <item>
  <title>Women Hit Harder in Healthcare Crisis: Study</title>
  <pubDate>Fri, 20 Apr 2007 11:26:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=471077&amp;cat_id=140</link>
  <description><![CDATA[Rising health costs are likely to hit women harder than men, especially as companies shift more costs to employees, according to a U.S. study released on Thursday.]]></description>
  </item>
  <item>
  <title>Chromosomes Tell Tale of Patient&#39;s Risk for New, Future Cancer</title>
  <pubDate>Wed, 18 Apr 2007 10:37:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=470811&amp;cat_id=140</link>
  <description><![CDATA[Hodgkin lymphoma survivors who have greater genetic instability in their white blood cells are two-and-a-half times more likely to develop another type of cancer, researchers report.]]></description>
  </item>
  <item>
  <title>Partners of Cancer Survivors at Risk for Depression</title>
  <pubDate>Tue, 10 Apr 2007 16:20:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=469843&amp;cat_id=140</link>
  <description><![CDATA[A new study shows that partners of cancer survivors are susceptible to the same stresses as cancer survivors themselves over the long term, and in some cases, suffer more quality of life-related effects than survivors]]></description>
  </item>
  <item>
  <title>Neuraminidase Inhibitor Effective against Influenza in Leukemia Patients</title>
  <pubDate>Thu, 05 Apr 2007 11:43:40 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=469025&amp;cat_id=140</link>
  <description><![CDATA[Neuraminidase inhibitors, which include oseltamivir and zanamivir, improve outcomes in leukemia patients with influenza, according to a report in the April 1st issue of Clinical Infectious Diseases.]]></description>
  </item>
  <item>
  <title>Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-Dose Steroid for Multiple Myeloma Treatment</title>
  <pubDate>Thu, 05 Apr 2007 09:30:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=468967&amp;cat_id=140</link>
  <description><![CDATA[Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron®), in combination with lenalidomide (Revlimid®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.]]></description>
  </item>
  <item>
  <title>ALL Treatment Outcomes Improved in Adolescents</title>
  <pubDate>Mon, 26 Mar 2007 09:12:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=467052&amp;cat_id=140</link>
  <description><![CDATA[Adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium protocols have better outcomes than published results from other studies, according to a report in the March 1st issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>University of Texas Researchers Publish Research on Drug with Potential to Reduce Risk of Graft-Versus-Host Disease</title>
  <pubDate>Thu, 22 Mar 2007 08:53:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466525&amp;cat_id=140</link>
  <description><![CDATA[Researchers at The University of Texas Southwestern Medical Center have discovered that a drug approved by the U.S. Food and Drug Administration (FDA) may significantly reduce graft-versus-host disease - a potentially life-threatening complication of stem cell transplants. The findings have been published online in the journal Biology of Blood and Marrow Transplantation.]]></description>
  </item>
  <item>
  <title>Genentech, Biogen Idec Add New Warning to Cancer Drug Rituxan</title>
  <pubDate>Wed, 21 Mar 2007 14:46:47 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466433&amp;cat_id=140</link>
  <description><![CDATA[Genentech Inc. and partner Biogen Idec must add a new warning about patients with lupus to the packaging for the cancer drug Rituxan®, according to the U.S. Food and Drug Administration (FDA).]]></description>
  </item>
  <item>
  <title>Two Novel Biologics Studied for Multiple Myeloma</title>
  <pubDate>Wed, 21 Mar 2007 14:42:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466430&amp;cat_id=140</link>
  <description><![CDATA[Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork Presbyterian Hospital/Weill Cornell Medical Center.]]></description>
  </item>
  <item>
  <title>Umbilical Blood Banks &#34;Take Advantage&#34; of Parents</title>
  <pubDate>Wed, 21 Mar 2007 12:59:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466389&amp;cat_id=140</link>
  <description><![CDATA[Besides choosing a car seat and setting up a college fund, Claire Rhye had one more decision to make before her first child arrived: what to do with her baby's umbilical cord blood.]]></description>
  </item>
  <item>
  <title>Treatment-Related Cardiotoxicity Persists for Hodgkin Lymphoma Survivors</title>
  <pubDate>Wed, 21 Mar 2007 12:58:09 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466386&amp;cat_id=140</link>
  <description><![CDATA[The improved prognosis for patients diagnosed with Hodgkin's lymphoma is challenged by the long-term cardiovascular sequelae of treatment. Multiple manifestations of cardiovascular disease (CVD) remain up to 5-fold higher than in the general population for more than 25 years, investigators report in the March 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>CHOP Alone Sufficient for Localized Aggressive Lymphoma in the Elderly</title>
  <pubDate>Wed, 21 Mar 2007 12:56:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466384&amp;cat_id=140</link>
  <description><![CDATA[Radiotherapy added to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) does not improve survival compared with CHOP alone in localized aggressive lymphoma in elderly patients, European investigators report in the March 1st issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Allograft from HLA-Identical Sibling Improves Myeloma Survival</title>
  <pubDate>Tue, 20 Mar 2007 10:38:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=466161&amp;cat_id=140</link>
  <description><![CDATA[Investigators in Italy and the US have developed a new protocol for treating patients with newly diagnosed multiple myeloma who have an HLA-identical sibling.]]></description>
  </item>
  <item>
  <title>Study Compares Stem Cell Transplants for Myeloma</title>
  <pubDate>Thu, 15 Mar 2007 10:57:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=465236&amp;cat_id=140</link>
  <description><![CDATA[Younger patients diagnosed with myeloma survived longer if they received a stem cell transplant from themselves that was followed by one from a matched sibling, rather than receiving two transplants from themselves, researchers report.]]></description>
  </item>
  <item>
  <title>Dexrazoxane Boosts Malignancies in Pediatric Hodgkin</title>
  <pubDate>Wed, 14 Mar 2007 13:49:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=464936&amp;cat_id=140</link>
  <description><![CDATA[Use of dexrazoxane to reduce cardiac toxicity is associated with increased risk of acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in young patients with Hodgkin's disease, according to a new study.]]></description>
  </item>
  <item>
  <title>FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents</title>
  <pubDate>Fri, 09 Mar 2007 14:56:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=463898&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) today issued a public health advisory outlining new safety information on the use of erythropoiesis-stimulating agents to treat anemia. These drigs include Aranesp® and Procrit®.]]></description>
  </item>
  <item>
  <title>Oblimersen Benefits Subset of Chronic Lymphocytic Leukemia Patients</title>
  <pubDate>Mon, 05 Mar 2007 10:50:16 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=462383&amp;cat_id=140</link>
  <description><![CDATA[Oblimersen (Genasense), an investigational antisense agent, has shown promise in a phase III study of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).]]></description>
  </item>
  <item>
  <title>Simple Revaccination Schedules Effective after Cancer Treatments</title>
  <pubDate>Mon, 05 Mar 2007 10:25:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=462371&amp;cat_id=140</link>
  <description><![CDATA[Simple revaccination schedules can increase protection against measles, tetanus, and other diseases in children who have received chemotherapy for leukemia or have undergone hematopoietic stem cell transplantation (HSCT), according to the findings of two studies appearing in Clinical Infectious Diseases for March 1.]]></description>
  </item>
  <item>
  <title>Children with Cancer Risk Fragile Bones</title>
  <pubDate>Tue, 27 Feb 2007 15:42:12 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=461365&amp;cat_id=140</link>
  <description><![CDATA[Physicians caring for children with cancer should be on the lookout for signs of bone fragility caused by disease and treatment, according to a new report.]]></description>
  </item>
  <item>
  <title>Novel Kinase Inhibitor Active against Some Refractory Leukemias</title>
  <pubDate>Thu, 22 Feb 2007 10:55:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=460134&amp;cat_id=140</link>
  <description><![CDATA[MK-0457, a novel kinase inhibitor, is effective against chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) that bear the T315I BCR-ABL mutation, according to a report in the January 15th issue of Blood.]]></description>
  </item>
  <item>
  <title>Hodgkin&#39;s Disease Therapy Increases MI Risk for Decades</title>
  <pubDate>Wed, 07 Feb 2007 11:37:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=457608&amp;cat_id=140</link>
  <description><![CDATA[Survivors of Hodgkin's disease may have an increased risk of fatal MI for up to 25 years after undergoing treatment, a British research team reports in the Journal of the National Cancer Institute for February 7. Most of the cardiotoxicity can be attributed to supradiaphragmatic radiotherapy, anthracyclines and vincristine.]]></description>
  </item>
  <item>
  <title>UCLA Researchers Discover Genes Linked to Lymphoma, Research Opens Way for New Targeted Drugs</title>
  <pubDate>Fri, 02 Feb 2007 11:11:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=456673&amp;cat_id=140</link>
  <description><![CDATA[Lymphoma is a blood cancer that affects more than 60,000 Americans each year. Researchers at The University of California Los Angeles (UCLA) have identified genes that when inactivated help cause B-cell non-Hodgkin lymphoma (NHL). These genetic defects may also be involved in promoting the formation of other cancers since they can inactivate normal tumor-suppressing gene activities in a range of cell types.]]></description>
  </item>
  <item>
  <title>Restoring p53 Gene Function May Help Fight Tumors</title>
  <pubDate>Wed, 31 Jan 2007 13:19:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=456264&amp;cat_id=140</link>
  <description><![CDATA[Drug developers have long wondered whether p53, one of the most commonly mutated genes in cancer, would make a good target for cancer therapies. Three new studies in mice suggest that it might.]]></description>
  </item>
  <item>
  <title>Arsenic Drug Helps Treat Acute Promyelocytic Leukemia</title>
  <pubDate>Mon, 29 Jan 2007 10:06:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=454887&amp;cat_id=140</link>
  <description><![CDATA[According to the Wall Street Journal, the National Institutes of Health (NIH) has said that adding an arsenic compound made by Cephalon Inc. to other treatments for adults with a rare form of leukemia significantly improved survival.]]></description>
  </item>
  <item>
  <title>Amgen Finds Anemia Drug Holds Risks in Cancer Use</title>
  <pubDate>Fri, 26 Jan 2007 14:01:25 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=455443&amp;cat_id=140</link>
  <description><![CDATA[Amgen has said that its anemia drug Aranesp increased the risk of death when used to treat certain cancer patients, a finding that will probably raise more questions about it and similar drugs. Read more.]]></description>
  </item>
  <item>
  <title>New Drug Therapy to Combat GVHD in Stem-Cell Patients Shows Significant Reduction in Deaths</title>
  <pubDate>Thu, 25 Jan 2007 13:22:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=454973&amp;cat_id=140</link>
  <description><![CDATA[Gastrointestinal graft-versus-host disease (GVHD) is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers. Now, new research from Fred Hutchinson Cancer Research Center shows that adding a widely used topical corticosteroid to the standard treatment for GVHD kept the disease in remission and significantly reduces deaths one year after therapy.]]></description>
  </item>
  <item>
  <title>Cooperative Agreement Appoved for U.S., Chinese Marrow Registries</title>
  <pubDate>Thu, 25 Jan 2007 13:16:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=454970&amp;cat_id=140</link>
  <description><![CDATA[A cooperative agreement between the National Marrow Donor Program (NMDP) and the Chinese Marrow Donor Program has been approved by the governments of both nations, allowing patients in the United States and China greater access to potential marrow donors in both countries.]]></description>
  </item>
  <item>
  <title>Posaconazole Surpasses Fluconazole As Antifungal Efficacy</title>
  <pubDate>Thu, 25 Jan 2007 13:06:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=454848&amp;cat_id=140</link>
  <description><![CDATA[The extended-spectrum triazole posaconazole appears to be more effective than fluconazole as prophylaxis among patients at risk for invasive fungal infections, particularly those due to invasive aspergillosis, according to two international, phase III trials reported in the January 25th issue of The New England Journal of Medicine. Survival may also be better when posaconazole is used.]]></description>
  </item>
  <item>
  <title>Researchers Develop New Strategy for the Treatment of CML</title>
  <pubDate>Thu, 25 Jan 2007 13:05:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=454827&amp;cat_id=140</link>
  <description><![CDATA[Virginia Commonwealth University Massey Cancer Center researchers have identified an approach to enhance the activity of a new anti-cancer agent that has already shown impressive efficacy in the treatment of chronic myelogenous leukemia (CML).]]></description>
  </item>
  <item>
  <title>Leukemia Halts Study of Prostate Cancer Drug</title>
  <pubDate>Mon, 22 Jan 2007 13:22:11 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=453839&amp;cat_id=140</link>
  <description><![CDATA[A cancer research consortium has halted a major study involving men with aggressive prostate cancer because the drug under study caused leukemia in three of 488 patients who received it.]]></description>
  </item>
  <item>
  <title>Smoking Increases Risk of Epstein-Barr Virus-Positive Hodgkin Lymphoma</title>
  <pubDate>Mon, 22 Jan 2007 10:15:53 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=453818&amp;cat_id=140</link>
  <description><![CDATA[Smoking increases the risk of Hodgkin lymphoma in general and the risk of Epstein-Barr virus-positive Hodgkin lymphoma in particular, a study published in the January issue of Epidemiology shows.]]></description>
  </item>
  <item>
  <title>Texas Study Finds Link Between Pollution, Cancer</title>
  <pubDate>Mon, 22 Jan 2007 10:14:13 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=453816&amp;cat_id=140</link>
  <description><![CDATA[University of Texas study found a possible link between childhood leukemia and living close to the city's refinery row along the Houston Ship Channel, one of the study's co-authors said on Thursday.]]></description>
  </item>
  <item>
  <title>Cancer Deaths Finally on Decline in United States: Survey</title>
  <pubDate>Thu, 18 Jan 2007 10:52:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=453352&amp;cat_id=140</link>
  <description><![CDATA[About 3,000 fewer people died from cancer in the United States from 2003 to 2004, the American Cancer Society reported on Wednesday.]]></description>
  </item>
  <item>
  <title>Immunochemotherapy Improves Outcome in Chronic Lymphocytic Leukemia</title>
  <pubDate>Wed, 17 Jan 2007 12:19:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=453219&amp;cat_id=140</link>
  <description><![CDATA[The addition of the monoclonal antibody rituximab to the chemotherapeutic agent fludarabine is associated with improved clinical outcome in patients with untreated chronic lymphocytic leukemia (CLL), suggest results of a study.]]></description>
  </item>
  <item>
  <title>Model Predicts Risk of Leukemia Induced by Radiation Therapy</title>
  <pubDate>Wed, 03 Jan 2007 15:02:34 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=450991&amp;cat_id=140</link>
  <description><![CDATA[A new analysis shows that it may be possible to accurately predict a cancer patient's risk of developing leukemia as a result of receiving radiation therapy for a primary tumor.]]></description>
  </item>
  <item>
  <title>Cancer-Related Seizure Responds to Treatment</title>
  <pubDate>Tue, 02 Jan 2007 10:46:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=450413&amp;cat_id=140</link>
  <description><![CDATA[A severe seizure that can be life-threatening called "status epilepticus" that can occur secondary to cancer or its treatment is responsive to anti-seizure treatment and does not adversely impact survival, new research shows.]]></description>
  </item>
  <item>
  <title>Not All FLT3 Mutations Worsen Prognosis in Pediatric AML</title>
  <pubDate>Tue, 02 Jan 2007 10:44:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=450410&amp;cat_id=140</link>
  <description><![CDATA[Only certain FLT3 mutations are associated with an increased risk for relapse in pediatric acute myeloid leukemia (AML), according to a report in the December 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Researchers Create Genetically Matched Embryonic Stem Cells for Transplantation</title>
  <pubDate>Mon, 18 Dec 2006 14:35:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=448652&amp;cat_id=140</link>
  <description><![CDATA[Researchers at Children's Hospital Boston report a new and efficient strategy, using eggs alone, for creating mouse embryonic stem cells that can be transplanted without the risk of rejection.]]></description>
  </item>
  <item>
  <title>Interim Analysis Finds Doxil/Velcade Combination Significantly Prolongs Time-to-Progression in Previously Treated Multiple Myeloma Patients</title>
  <pubDate>Tue, 12 Dec 2006 13:42:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447917&amp;cat_id=140</link>
  <description><![CDATA[Researchers report that the combination of medications provides a nearly three-month improvement in time-to-disease progression in the treatment of relapsed/refractory multiple myeloma patients versus Velcade alone.]]></description>
  </item>
  <item>
  <title>Phase III Comparative Study Shows Campath Superior to Chlorambucil as a First-line Therapy in B-CLL</title>
  <pubDate>Tue, 12 Dec 2006 13:36:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447912&amp;cat_id=140</link>
  <description><![CDATA[Genzyme Corp. and Berlex Inc.have announced results from CAM307, an international Phase III clinical trial comparing Campath (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia.]]></description>
  </item>
  <item>
  <title>After Two Years, Study Continues to Show Patients Treated with Revlimid Are Living Longer and Remaining Transfusion Independent</title>
  <pubDate>Tue, 12 Dec 2006 13:33:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447910&amp;cat_id=140</link>
  <description><![CDATA[Read more about this breakthrough study on patients with myelodysplastic syndromes.]]></description>
  </item>
  <item>
  <title>Chronic Lymphocytic Leukemia Patients Respond to Lenalidomide</title>
  <pubDate>Tue, 12 Dec 2006 13:30:27 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447907&amp;cat_id=140</link>
  <description><![CDATA[Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia or who have chemo-resistant disease may have a new option for therapy.]]></description>
  </item>
  <item>
  <title>Drug Combination Proves Effective against Myeloma in Phase I Trial</title>
  <pubDate>Tue, 12 Dec 2006 13:28:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447886&amp;cat_id=140</link>
  <description><![CDATA[Two "new generation" drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial.]]></description>
  </item>
  <item>
  <title>Biogen Says Leukemia Drug Shows Promise in Trial</title>
  <pubDate>Tue, 12 Dec 2006 10:04:41 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447655&amp;cat_id=140</link>
  <description><![CDATA[Biogen Idec Inc. said on Sunday that its experimental leukemia drug showed promise in a mid-stage trial, paving the way for a more advanced trial to start early next year.]]></description>
  </item>
  <item>
  <title>Celgene&#39;s Revlimid Beneficial in Leukemia Trial</title>
  <pubDate>Tue, 12 Dec 2006 10:03:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447653&amp;cat_id=140</link>
  <description><![CDATA[Celgene Inc. said on Monday that its cancer drug Revlimid, approved to treat the bone marrow cancer multiple myeloma, also showed promise as a treatment for leukemia in a mid-stage clinical trial.]]></description>
  </item>
  <item>
  <title>Novartis Says Leukemia Drug Helps When Gleevec Fails</title>
  <pubDate>Tue, 12 Dec 2006 10:01:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447651&amp;cat_id=140</link>
  <description><![CDATA[Novartis AG said on Monday its experimental leukemia drug works in about half of all patients who develop resistance to Gleevec, the leading drug for the most common type of chronic myeloid leukemia, or CML.]]></description>
  </item>
  <item>
  <title>Velcade Approved for Mantle Cell Lymphoma</title>
  <pubDate>Mon, 11 Dec 2006 11:29:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=447264&amp;cat_id=140</link>
  <description><![CDATA[Millennium Pharmaceuticals Inc. said on Friday it won U.S. approval to market Velcade (bortezomib) for patients with an aggressive form of non-Hodgkin's lymphoma.]]></description>
  </item>
  <item>
  <title>Imatinib Provides Highest Long-Term Survival for Chronic Leukemia</title>
  <pubDate>Thu, 07 Dec 2006 10:30:08 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=446339&amp;cat_id=140</link>
  <description><![CDATA[As an initial and continued treatment for chronic myeloid leukemia (CML), imatinib (Gleevec/Glivec) is associated with a 5-year overall survival rate of 89%, the highest rate ever seen in a published prospective study of CML therapy, new research shows.]]></description>
  </item>
  <item>
  <title>Bortezomib and Thalidomide May Benefit Elderly with Multiple Myeloma</title>
  <pubDate>Tue, 28 Nov 2006 09:52:32 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=444537&amp;cat_id=140</link>
  <description><![CDATA[The addition of bortezomib or thalidomide to conventional chemotherapy to treat elderly patients with multiple myeloma improves response rates and prolongs survival, according to results of two prospective trials reported in the October issue of Blood. In both studies, side effects were "predictable and manageable," and serious adverse events were rare.]]></description>
  </item>
  <item>
  <title>Doxorubicin Helpful in Elderly Lymphoma Patients</title>
  <pubDate>Mon, 27 Nov 2006 10:04:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=444372&amp;cat_id=140</link>
  <description><![CDATA[New York oncologists confirm the safety and efficacy of using doxorubicin (Adriamycin, Pharmacia) as part of a chemotherapy regimen for elderly patients with aggressive, non-Hodgkin's lymphoma (NHL).]]></description>
  </item>
  <item>
  <title>Campath Safe and Active in Patients with CLL after Extensive Prior Therapy</title>
  <pubDate>Thu, 16 Nov 2006 16:29:44 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=443485&amp;cat_id=140</link>
  <description><![CDATA[A study reported in the journal Cancer confirms the anticancer activity and safety of Campath® (alemtuzumab) in the treatment of chronic lymphocytic leukemia (CLL) among patients who have received prior therapies.]]></description>
  </item>
  <item>
  <title>The Society, Ensemble Discovery Corp. Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers</title>
  <pubDate>Wed, 15 Nov 2006 10:44:45 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=443008&amp;cat_id=140</link>
  <description><![CDATA[Marking the launch of its new initiative to accelerate the development of blood cancer therapies, The Leukemia & Lymphoma Society today announced a collaboration with Ensemble Discovery Corp. of Cambridge, MA.]]></description>
  </item>
  <item>
  <title>Doxil, Oncovin, Revlimid and Dexamethasone Effective in Recurrent Multiple Myeloma</title>
  <pubDate>Mon, 06 Nov 2006 13:00:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=441454&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in the Annals of Oncology, a treatment combination of Revlimid® (lenalidomide), Oncovin® (vincristine), Doxil® (pegylated doxorubicin) and dexamethasone appears highly effective in multiple myeloma that has recurred or progressed following prior therapies. Read more.]]></description>
  </item>
  <item>
  <title>Early Treatment for Anemia Improves Quality of Life for Patients Undergoing Chemotherapy</title>
  <pubDate>Wed, 25 Oct 2006 15:33:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=439830&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in the journal Cancer, treatment with Procrit® (epoetin alfa) for mild anemia improves quality of life and patient productivity among individuals undergoing chemotherapy.]]></description>
  </item>
  <item>
  <title>U.S. OKs Gleevec for Five Rare Diseases</title>
  <pubDate>Mon, 23 Oct 2006 11:40:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=439463&amp;cat_id=140</link>
  <description><![CDATA[Swiss drugmaker Novartis AG won U.S. permission on Thursday to market the cancer drug Gleevec (imatinib), known as Glivec in Europe, for treating five rare and potentially life-threatening diseases, the company said.]]></description>
  </item>
  <item>
  <title>Thioguanine Too Toxic for Maintenance Treatment of Childhood Leukemia</title>
  <pubDate>Mon, 16 Oct 2006 14:19:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=437828&amp;cat_id=140</link>
  <description><![CDATA[Because of its hepatotoxicity and its increased risk of fatal infection, 6-thioguanine should not replace 6-mercaptopurine as the optimal continuing therapy in children with lymphoblastic leukemia in remission, UK researchers report in the October 14th issue of The Lancet.]]></description>
  </item>
  <item>
  <title>U.S. Food and Drug Administration Approves New Treatment for Cutaneous T-Cell Lymphoma</title>
  <pubDate>Wed, 11 Oct 2006 09:25:45 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=436799&amp;cat_id=140</link>
  <description><![CDATA[On Oct. 6, 2006, the U.S. Food and Drug Administration granted approval to vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.]]></description>
  </item>
  <item>
  <title>C/EBP-Alpha Protein Promising against Leukemia</title>
  <pubDate>Tue, 10 Oct 2006 11:15:34 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=436697&amp;cat_id=140</link>
  <description><![CDATA[Re-activation of the transcription factor C/EBP-alpha leads to suppression of chronic myelogenous leukemia (CML) and may restore sensitivity to BCR/ABL tyrosine kinase inhibitors, e.g., Gleevec/Glivec. Downregulation of C/EBP-alpha appears to be important in progression of CML, according to researchers.]]></description>
  </item>
  <item>
  <title>Doxycycline Seen Effective for Lymphoma of the Eye</title>
  <pubDate>Tue, 10 Oct 2006 11:12:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=436691&amp;cat_id=140</link>
  <description><![CDATA[Doxycycline is a "fast, safe, and active" therapy for ocular adnexal lymphoma (OAL) of the MALT type, both initially and in the case of relapse, clinicians report in the current issue of the Journal of the National Cancer Institute dated October 4.]]></description>
  </item>
  <item>
  <title>Researchers Uncover Clues that May Lead to Better Therapies for Children with T-Cell Acute Lymphocytic Leukemia</title>
  <pubDate>Thu, 05 Oct 2006 15:53:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=432718&amp;cat_id=140</link>
  <description><![CDATA[Researchers' discovery of clues to the cause of T-cell acute lymphoblastic leukemia (T-ALL) - a form of pediatric cancer that has a very poor prognosis - could lead to the development of new targeted therapies for this extremely difficult disease.]]></description>
  </item>
  <item>
  <title>The Leukemia &amp; Lymphoma Society Unveils New Education Series for Myeloma Patients, Covers Latest Research and Treatment Options</title>
  <pubDate>Thu, 05 Oct 2006 15:53:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=432970&amp;cat_id=140</link>
  <description><![CDATA[The Leukemia & Lymphoma Society has created a new myeloma telephone education series to provide patients, their families and healthcare professionals with the most up-to-date information about the disease, a cancer of plasma cells that starts in the bone marrow. It is one of the most difficult blood cancers to treat successfully, but today advances in therapies provide patients with more choices than ever before]]></description>
  </item>
  <item>
  <title>Idiotypic Vaccination Benefits Patients with Follicular Lymphoma</title>
  <pubDate>Mon, 02 Oct 2006 16:53:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=435387&amp;cat_id=140</link>
  <description><![CDATA[Idiotypic vaccination significantly improves disease-free survival in patients with follicular lymphoma in first relapse, according to a report in the September 20th Journal of the National Cancer Institute.]]></description>
  </item>
  <item>
  <title>U.S. Approves Additional Uses for Rituxan</title>
  <pubDate>Mon, 02 Oct 2006 16:50:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=435379&amp;cat_id=140</link>
  <description><![CDATA[On September 29, 2006, the U.S. Food and Drug Administration approved two rituximab (Rituxan®, Genentech, Inc.) supplemental applications for the first-line treatment of patients with low grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma. One approval was for the use of Rituxan® combined with CVP chemotherapy (cyclophosphamide, vincristine, and prednisone); the second is for use of Rituxan® following CVP chemotherapy.]]></description>
  </item>
  <item>
  <title>Gleevec Granted Accelerated Approval for Children Newly Diagnosed with Chronic Myelogenous Leukemia</title>
  <pubDate>Fri, 29 Sep 2006 14:12:36 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=435149&amp;cat_id=140</link>
  <description><![CDATA["On September 27, 2006, the U.S. Food and Drug Administration granted accelerated approval to imatinib mesylate (Gleevec®, Novartis Pharmaceuticals) as a single agent for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).]]></description>
  </item>
  <item>
  <title>U.S. Approves New Cancer Pain Drug</title>
  <pubDate>Tue, 26 Sep 2006 17:29:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=434328&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration said on Monday it had approved Cephalon Inc.'s drug Fentora to treat pain in certain cancer patients.]]></description>
  </item>
  <item>
  <title>PET Imaging Improves Accuracy of Childhood Hodgkin Lymphoma Staging</title>
  <pubDate>Tue, 26 Sep 2006 09:28:04 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=434173&amp;cat_id=140</link>
  <description><![CDATA[The addition of PET imaging to conventional imaging modalities (ultrasound, CT, and MRI) improves the accuracy of staging in children with Hodgkin's disease, according to a report by investigators in Germany.]]></description>
  </item>
  <item>
  <title>No Increased Lymphoma Risk Seen with Ankylosing Spondylitis</title>
  <pubDate>Mon, 25 Sep 2006 15:01:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=434080&amp;cat_id=140</link>
  <description><![CDATA[The risk for malignant lymphoma does not appear to be increased among patients hospitalized with ankylosing spondylitis (AS), according to a report from Sweden.]]></description>
  </item>
  <item>
  <title>Vaccination Increases Survival in Lymphoma Patients</title>
  <pubDate>Mon, 25 Sep 2006 14:58:30 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=434077&amp;cat_id=140</link>
  <description><![CDATA[Idiotypic vaccination can increase the survival times of follicular lymphoma patients. Read more.]]></description>
  </item>
  <item>
  <title>Bisphosphonates Should Be Used with Caution for Multiple Myeloma</title>
  <pubDate>Mon, 28 Aug 2006 11:55:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=430341&amp;cat_id=140</link>
  <description><![CDATA[Bisphosphonates should be used cautiously and for limited periods to prevent or treat bone disease in patients with multiple myeloma, according to a consensus statement by a multidisciplinary panel at the Mayo Clinic.]]></description>
  </item>
  <item>
  <title>Treatment with High-Dose Chemotherapy, Autologous Transplant and Radiation Effective for Primary Central Nervous System Lymphoma</title>
  <pubDate>Thu, 24 Aug 2006 14:56:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=430200&amp;cat_id=140</link>
  <description><![CDATA[According to an early online publication in the Journal of Clinical Oncology, high-dose chemotherapy and whole-brain radiation may be an effective treatment for primary central nervous system lymphoma.]]></description>
  </item>
  <item>
  <title>Study: Petrochemical Exposure Raises Leukemia Risk in Young Adults</title>
  <pubDate>Fri, 04 Aug 2006 10:45:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=427787&amp;cat_id=140</link>
  <description><![CDATA[Residential exposure to petrochemicals is associated with an elevated risk of leukemia among adults in their 20s, according to a report in the American Journal of Epidemiology for August 1.]]></description>
  </item>
  <item>
  <title>Idiotype Vaccine Can Prompt Lymphoma Tumor Regression</title>
  <pubDate>Tue, 01 Aug 2006 10:31:45 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=427104&amp;cat_id=140</link>
  <description><![CDATA[patient-specific idiotype (Id) vaccine induces tumor regression in certain patients with indolent non-Hodgkin's lymphoma, researchers report in the July 1st issue of the Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>Early Reduced-Intensity Stem Cell Transplantation Promising for Acute Myeloid Leukemia</title>
  <pubDate>Fri, 28 Jul 2006 13:06:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=426794&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in the journal Blood, a novel regimen used as part of a reduced-intensity, or "mini," stem cell transplant produces impressive survival rates among older adult patients with acute myeloid leukemia (AML) that has stopped responding to prior therapy.]]></description>
  </item>
  <item>
  <title>Anemic Children with Cancer Benefit from Erythropoietin</title>
  <pubDate>Fri, 28 Jul 2006 10:58:01 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=426749&amp;cat_id=140</link>
  <description><![CDATA[Children with cancer who develop anemia during chemotherapy can benefit from a weekly dose of erythropoietin, according to researchers at St. Jude Children's Research Hospital.]]></description>
  </item>
  <item>
  <title>FDA Approves Oncaspar for Newly-Diagnosed Acute Lymphoblastic Leukemia</title>
  <pubDate>Tue, 25 Jul 2006 10:48:21 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=426382&amp;cat_id=140</link>
  <description><![CDATA[The Food and Drug Administration (FDA) today expanded the approved use of Oncaspar to include treating children and adults with newly diagnosed acute lymphoblastic leukemia (ALL) as part of a multiple drug chemotherapy regimen. The FDA previously approved Oncaspar in 1994 only for patients with ALL who were unable to receive the cancer drug L-asparaginase because they were allergic to that drug.]]></description>
  </item>
  <item>
  <title>Thalidomide Boosts Multiple Myeloma Therapy Response</title>
  <pubDate>Wed, 19 Jul 2006 15:37:12 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=425932&amp;cat_id=140</link>
  <description><![CDATA[The addition of thalidomide to pegylated liposomal doxorubicin and vincristine, along with decreased-frequency dexamethasone, leads to an improved response in patients with multiple myeloma, researchers report in the July issue of Mayo Clinic Proceedings.]]></description>
  </item>
  <item>
  <title>Teens Need Specialized Cancer Care</title>
  <pubDate>Tue, 18 Jul 2006 17:05:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=425793&amp;cat_id=140</link>
  <description><![CDATA[Read about the special needs of teen cancer patients]]></description>
  </item>
  <item>
  <title>Bcl-6 Protein Expression Guides Treatment of Large B-Cell Lymphoma</title>
  <pubDate>Tue, 18 Jul 2006 15:15:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=425719&amp;cat_id=140</link>
  <description><![CDATA[Patients with Bcl-6 protein-negative diffuse large B cell lymphoma (DLBCL) benefit from the addition of rituximab to traditional CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), a multi-center team of oncologists report in the June 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>Clinical Trials Running Out of Volunteers: Research Shows</title>
  <pubDate>Tue, 18 Jul 2006 15:13:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=425717&amp;cat_id=140</link>
  <description><![CDATA[What if you organized an important cancer clinical trial and nobody came? That scenario could become a reality for oncology researchers across the United States, new research shows.]]></description>
  </item>
  <item>
  <title>Rituxan Effective in Treatment of Splenic Marginal Zone Lymphoma and Marginal Zone Lymphoma</title>
  <pubDate>Tue, 18 Jul 2006 15:09:19 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=425712&amp;cat_id=140</link>
  <description><![CDATA[According to the results of a study published in the journal Cancer, the targeted therapy Rituxan® (rituximab) appears to be effective in the treatment of two relatively uncommon types of non-Hodgkin lymphoma—splenic marginal zone lymphoma and marginal zone lymphoma.]]></description>
  </item>
  <item>
  <title>Childhood Cancer Survivors Are More Likely to Go Through Early Menopause</title>
  <pubDate>Wed, 05 Jul 2006 11:39:15 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=423170&amp;cat_id=140</link>
  <description><![CDATA[Women who survive childhood cancer are more likely to suffer premature menopause, according to a study in the Journal of the National Cancer Institute.]]></description>
  </item>
  <item>
  <title>Ocular Lymphoma Rates Increasing in United States with No Sign of Peak</title>
  <pubDate>Wed, 05 Jul 2006 11:35:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=423165&amp;cat_id=140</link>
  <description><![CDATA[From 1975 to 2001, a rapid and steady rise in the rate of ocular non-Hodgkin lymphoma (NHL) occurred, and there is still no evidence the disease has peaked, according to a new report.]]></description>
  </item>
  <item>
  <title>Cost a Barrier to Care for Many U.S. Cancer Survivors</title>
  <pubDate>Wed, 05 Jul 2006 10:06:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=423146&amp;cat_id=140</link>
  <description><![CDATA[One in five cancer survivors younger than 65 delay getting necessary care, or may not receive such care at all, due to cost, a new study shows.]]></description>
  </item>
  <item>
  <title>U.S. FDA Approves Revlimid for Multiple Myeloma</title>
  <pubDate>Mon, 03 Jul 2006 13:07:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=423031&amp;cat_id=140</link>
  <description><![CDATA[Celgene Corp. said on Thursday that U.S. health regulators have approved Revlimid to treat multiple myeloma in patients who have failed to respond to a previous treatment.]]></description>
  </item>
  <item>
  <title>FDA Gives Rapid Approval for New CML Treatment</title>
  <pubDate>Thu, 29 Jun 2006 16:34:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=422536&amp;cat_id=140</link>
  <description><![CDATA[The U.S., Food and Drug Administration (FDA) granted accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML).]]></description>
  </item>
  <item>
  <title>After a Loss, &#34;Complicated Grief&#34; May Set In</title>
  <pubDate>Mon, 26 Jun 2006 10:05:45 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=421311&amp;cat_id=140</link>
  <description><![CDATA[It's normal to feel sadness and grief with the passing of a loved one, but an intense and persistent yearning for the person who died, difficulties "moving on" with life after a period of time, and a sense that life and the future are meaningless and purposelessness, are signs of "complicated grief," warns a group of Dutch doctors.]]></description>
  </item>
  <item>
  <title>Modified Regimen Reduces Neutropenia in CLL</title>
  <pubDate>Wed, 21 Jun 2006 09:13:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=420547&amp;cat_id=140</link>
  <description><![CDATA[According to results recently presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), modified doses of the regimen including Rituxan® (rituximab), Fludara® (fludarabine) and cyclophosphamide—referred to as mFCR—provides high anticancer activity with fewer side effects in untreated chronic lymphocytic leukemia.]]></description>
  </item>
  <item>
  <title>Tobacco Use, BMI Not Linked to Malignant Lymphoma Risk</title>
  <pubDate>Wed, 21 Jun 2006 09:10:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=420545&amp;cat_id=140</link>
  <description><![CDATA[Tobacco use and high body mass index (BMI) are not associated with an increased risk of non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD), investigators from Sweden and France report.]]></description>
  </item>
  <item>
  <title>ATRA Plus Arsenic Trioxide Effective in Untreated Acute Promyelocytic Leukemia</title>
  <pubDate>Fri, 16 Jun 2006 14:55:05 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=419867&amp;cat_id=140</link>
  <description><![CDATA[The combination of all-trans retinoic acid (ATRA) and arsenic trioxide may be an alternative to chemotherapy for low-risk untreated acute promyelocytic leukemia (APL), according to a report in the May 1st issue of Blood.]]></description>
  </item>
  <item>
  <title>New Leukemia Drugs Help Those Who Fail Gleevec</title>
  <pubDate>Thu, 15 Jun 2006 15:31:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=419669&amp;cat_id=140</link>
  <description><![CDATA[The prognosis picture for people with chronic myelogenous leukemia (CML) has just gotten even rosier.]]></description>
  </item>
  <item>
  <title>New BCR-ABL Inhibitors Active Against Imatinib-Resistant Leukemias</title>
  <pubDate>Thu, 15 Jun 2006 15:29:57 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=419667&amp;cat_id=140</link>
  <description><![CDATA[Dasatinib and nilotinib, two recently developed BCR-ABL inhibitors, can produce a therapeutic response in Philadelphia chromosome (Ph)-positive leukemias resistant to the older BCR-ABL inhibitor imatinib (Gleevec/Glivec), according to the results of two studies in The New England Journal of Medicine for June 15.]]></description>
  </item>
  <item>
  <title>June 2006 Commentary</title>
  <pubDate>Mon, 12 Jun 2006 11:40:37 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_page.adp?item_id=418670</link>
  <description><![CDATA[In the February Links, I described new “targeted” blood cancer treatments. These revolutionary therapies, which kill cancer cells efficiently while sparing normal cells, cause fewer side effects than standard treatments. They take advantage of our increasing understanding of the genes that cause various cancers.]]></description>
  </item>
  <item>
  <title>Further Evidence that Vidaza Reduces Need for Transfusions in Myelodysplastic Syndromes</title>
  <pubDate>Fri, 09 Jun 2006 11:41:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=418583&amp;cat_id=140</link>
  <description><![CDATA[According to results recently presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), further evaluation of data demonstrates that the agent Vidaza® (azacitadine) reduces the need for red blood cell and platelet transfusions in a significant portion of patients with myelodysplastic syndromes (MDS).]]></description>
  </item>
  <item>
  <title>New Research on the Mechanisms that Control Blood Cells of Acute Myelogenous Leukemia Patients May Lead to Better Targeted Therapies</title>
  <pubDate>Fri, 09 Jun 2006 10:55:39 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=418574&amp;cat_id=140</link>
  <description><![CDATA[New findings to be published in the journal Blood strongly suggest that new drugs under development for acute myelogenous leukemia (AML) patients would be much more effective if used in specific combinations most appropriate to the individual patient, leading to better and more specifically targeted therapies for these patients with fewer side-effects.]]></description>
  </item>
  <item>
  <title>Novartis Plans Earlier CML Drug Application</title>
  <pubDate>Tue, 06 Jun 2006 15:13:14 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417910&amp;cat_id=140</link>
  <description><![CDATA[Novartis AG said on Sunday it plans to submit its application with U.S. regulators to market its new treatment-resistant chronic myelogenous leukemia (CML) drug, nilotinib, earlier than expected.]]></description>
  </item>
  <item>
  <title>Combination &#34;Smart Bombs&#34; Future of Cancer Therapy</title>
  <pubDate>Tue, 06 Jun 2006 10:20:28 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417778&amp;cat_id=140</link>
  <description><![CDATA[Using combinations of "smart bomb" cancer drugs that target specific proteins and avoid the indiscriminate cell destruction of chemotherapy may be the wave of the future for cancer patients, experts say.]]></description>
  </item>
  <item>
  <title>Celgene Drug Boosts Multiple Myeloma Survival: Study</title>
  <pubDate>Tue, 06 Jun 2006 10:19:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417776&amp;cat_id=140</link>
  <description><![CDATA[Celgene Inc. said on Sunday its cancer drug Thalomid improved survival by a significant amount in elderly patients with multiple myeloma, a form of blood cancer.]]></description>
  </item>
  <item>
  <title>Schering Says Leukemia Drug MabCampath Promising</title>
  <pubDate>Tue, 06 Jun 2006 10:18:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417774&amp;cat_id=140</link>
  <description><![CDATA[German drugmaker Schering AG and U.S. biotech firm Genzyme Corp have seen good preliminary results in a study of the drug MabCampath to treat leukemia, Schering said in a statement.]]></description>
  </item>
  <item>
  <title>Revlimid Boosts Survival in Multiple Myeloma: Study</title>
  <pubDate>Tue, 06 Jun 2006 10:16:03 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417772&amp;cat_id=140</link>
  <description><![CDATA[Celgene Inc.'s cancer drug Revlimid improves the rate of survival in previously treated patients with the blood cancer multiple myeloma by at least a year compared with those taking standard treatment, according to data released on Monday.]]></description>
  </item>
  <item>
  <title>U.S. Advisers Back Bristol-Myers Leukemia Drug</title>
  <pubDate>Mon, 05 Jun 2006 09:28:54 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417618&amp;cat_id=140</link>
  <description><![CDATA[Bristol-Myers Squibb Co.'s experimental drug Sprycel (dasatinib) should be approved for treating two types of leukemia in patients who have few if any other options, a U.S. advisory panel said on Friday.]]></description>
  </item>
  <item>
  <title>Drug for Bones Is Newly Linked to Jaw Disease</title>
  <pubDate>Fri, 02 Jun 2006 11:37:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417581&amp;cat_id=140</link>
  <description><![CDATA[According to The New York Times, patients taking a class of drugs that can prevent broken and deteriorating bones, have an increased risk of serious jaw disease.]]></description>
  </item>
  <item>
  <title>Ice Chips Prevent Mouth Sores Associated with High-Dose Chemotherapy</title>
  <pubDate>Thu, 01 Jun 2006 14:01:29 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417525&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in Bone Marrow Transplantation, sucking on ice chips may help to prevent oral mucositis associated with high doses of the chemotherapy agent Alkeran® (melphalan).]]></description>
  </item>
  <item>
  <title>ASCO Updates Guidelines for Use of Antiemetics in Cancer Therapy</title>
  <pubDate>Wed, 31 May 2006 10:46:56 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417299&amp;cat_id=140</link>
  <description><![CDATA[The American Society of Clinical Oncology has issued new clinical practice guidelines on emesis management in cancer patients receiving chemotherapy or radiation. The new guidelines will be published in the June 20th issue of the Journal of Clinical Oncology and are currently available online at www.jco.org.]]></description>
  </item>
  <item>
  <title>Ovarian Failure Relatively Rare after Childhood Cancer</title>
  <pubDate>Wed, 31 May 2006 10:45:17 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417297&amp;cat_id=140</link>
  <description><![CDATA[Acute ovarian failure (AOF) occurs in a "small subset" of survivors of childhood cancer, most notably in those treated with higher levels of ovarian irradiation, researchers report in the May issue of the Journal of Clinical Endocrinology and Metabolism.]]></description>
  </item>
  <item>
  <title>Sterility Uncommon in Women after Childhood Cancer</title>
  <pubDate>Wed, 31 May 2006 09:39:46 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417285&amp;cat_id=140</link>
  <description><![CDATA[Only a small subset of women who survive childhood cancer will become sterile as a result of their cancer treatment. In these cases, sterility develops as a result of "acute ovarian failure," when the ovaries shut down, and most commonly occurs after high levels of ovarian radiation, researchers report in the Journal of Clinical Endocrinology and Metabolism.]]></description>
  </item>
  <item>
  <title>No link Between Leukemia Risk and Nuclear Plants: French Study</title>
  <pubDate>Wed, 31 May 2006 09:38:00 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417283&amp;cat_id=140</link>
  <description><![CDATA[Children living near nuclear plants in France do not have an increased risk of leukemia, a new study confirms.]]></description>
  </item>
  <item>
  <title>U.S. Government Approves Celgene Drug Thalomid for Multiple Myeloma</title>
  <pubDate>Tue, 30 May 2006 10:40:23 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=417167&amp;cat_id=140</link>
  <description><![CDATA[Celgene Corp. won U.S. approval on Thursday to promote its drug Thalomid for treating patients newly diagnosed with the blood cancer multiple myeloma.]]></description>
  </item>
  <item>
  <title>Society-Funded Researchers Identify Genetic Defects That Cause Main Types of Non-Hodgkin Lymphoma, Paving the Way for Potential New Targeted Therapies</title>
  <pubDate>Fri, 26 May 2006 11:28:10 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=416968&amp;cat_id=140</link>
  <description><![CDATA[Researchers will report on the discovery of genetic defects that cause particular types of non-Hodgkin lymphoma (NHL), making these genes rational targets for new anti-lymphoma treatments, in the next issue of Blood.]]></description>
  </item>
  <item>
  <title>New Guidelines Focus on Preventing Chemo&#39;s Side Effects</title>
  <pubDate>Wed, 24 May 2006 11:00:58 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=416703&amp;cat_id=140</link>
  <description><![CDATA[Cancer experts at the American Society of Clinical Oncology (ASCO) have issued new guidelines on using antiemetic drugs to prevent nausea and vomiting in patients who receive chemotherapy or radiation treatment.]]></description>
  </item>
  <item>
  <title>School Performance Affected by Treatment of ALL</title>
  <pubDate>Wed, 24 May 2006 10:05:52 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=416688&amp;cat_id=140</link>
  <description><![CDATA[Following treatment for acute lymphoblastic leukemia (ALL), children exhibit a moderately increased risk of behavioral and education problems, Dutch researchers report. An additional finding that children treated for Wilms tumor are not affected suggests that neurotoxic chemotherapy used to treat ALL may be responsible for the deficits observed in this group.]]></description>
  </item>
  <item>
  <title>New Parameters Help Distinguish Juvenile Rheumatoid Arthritis from Acute Lymphocytic Leukemia</title>
  <pubDate>Thu, 18 May 2006 09:49:48 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=415005&amp;cat_id=140</link>
  <description><![CDATA[A retrospective study reported in the May issue of Pediatrics suggests parameters for distinguishing juvenile rheumatoid arthritis from acute lymphocytic leukemia.]]></description>
  </item>
  <item>
  <title>Cancer Drug Gleevec Can Interfere with Bone Growth</title>
  <pubDate>Wed, 17 May 2006 15:39:02 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=414335&amp;cat_id=140</link>
  <description><![CDATA[Gleevec®, the drug that has brought life and hope to patients with some otherwise untreatable cancers, can interfere with bone formation, researchers have found.  It's a side effect, they say, that deserves careful watching but should not stop use of the medication.]]></description>
  </item>
  <item>
  <title>Five Years After Approval, Gleevec Underscores the Promise of Targeted Therapies</title>
  <pubDate>Wed, 10 May 2006 16:32:26 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=414231&amp;cat_id=140</link>
  <description><![CDATA[Marking an important milestone since its first approval in May 2001, Gleevec® has become the first oncology drug to be validated as an effective and generally well-tolerated edicine that targets a specific cause of a cancer.]]></description>
  </item>
  <item>
  <title>Polio Vaccine Not Tied to Non-Hodgkin Lymphoma</title>
  <pubDate>Wed, 10 May 2006 10:24:38 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413857&amp;cat_id=140</link>
  <description><![CDATA[Norwegian researchers report finding no support for the proposed link between a polio vaccine possibly contaminated with simian virus 40 (SV40) and lymphoproliferative diseases, including non-Hodgkin's lymphoma (NHL) and excluding Hodgkin's lymphoma.]]></description>
  </item>
  <item>
  <title>Atypical Lymphoid Tissue Lymphoma May Respond to Antibiotics</title>
  <pubDate>Wed, 10 May 2006 10:24:17 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413859&amp;cat_id=140</link>
  <description><![CDATA[Antibiotic treatment may be effective for patients with early stage gastric mucosa associated lymphoid tissue (MALT) lymphoma, but are negative for Helicobacter pylori, Austrian researchers report in the May issue of Gut.]]></description>
  </item>
  <item>
  <title>White Race Increases Hypothyroidism Risk after Hodgkin Lymphoma Treatment</title>
  <pubDate>Wed, 10 May 2006 10:23:49 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413991&amp;cat_id=140</link>
  <description><![CDATA[White patients face a higher risk than black patients for becoming hypothyroid after neck irradiation for pediatric Hodgkin's lymphoma, according to a report in the April 1st Journal of Clinical Oncology.]]></description>
  </item>
  <item>
  <title>May 2006 Commentary</title>
  <pubDate>Tue, 09 May 2006 16:49:31 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_page.adp?item_id=413951</link>
  <description><![CDATA[This month’s topic is epigenetics, which refers to changes that stably alter gene activities without changing, or mutating, the DNA sequence of those genes. Like genetic mutations, we now know that epigenetic abnormalities can cause cancers, including blood cancers. And, as with cancer-causing mutations, laboratory and clinical studies are now showing that drugs that target specific “epigenetic” changes will be powerful treatments for blood cancer patients.]]></description>
  </item>
  <item>
  <title>Acupuncture May Control Vomiting after Chemo</title>
  <pubDate>Thu, 04 May 2006 11:37:18 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413452&amp;cat_id=140</link>
  <description><![CDATA[Acupuncture, in conjunction with the latest drugs to prevent nausea and vomiting, seems to help relieve chemotherapy-induced vomiting, a new report suggests.]]></description>
  </item>
  <item>
  <title>Elderly Patients with Non-Hodgkin Lymphoma Tolerate Autologous Stem Cell Transplantation</title>
  <pubDate>Thu, 04 May 2006 10:12:33 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413404&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in Bone Marrow Transplantation, elderly patients with non-Hodgkin lymphoma are able to tolerate autologous stem cell transplantation. However, it is important for all patients to discuss their individual risks of stem cell transplantation with their physician.]]></description>
  </item>
  <item>
  <title>FDA Approves Decitabine for Injection for Myelodysplastic Syndromes</title>
  <pubDate>Wed, 03 May 2006 12:36:59 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=413278&amp;cat_id=140</link>
  <description><![CDATA[The U.S. Food and Drug Administration (FDA) has approved decitabine for injection (Dacogen®, MGI Pharma Inc.) for the treatment of patients with myelodysplastic syndromes.]]></description>
  </item>
  <item>
  <title>Circulating Cancer Cells Indicate Worse Outcomes Following Autologous Stem Cell Transplantation in Multiple Myeloma</title>
  <pubDate>Wed, 26 Apr 2006 10:45:24 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=412462&amp;cat_id=140</link>
  <description><![CDATA[According to an article recently published in the journal Blood, the presence of cancer cells circulating in the blood is associated with a less favorable prognosis following an autologous stem cell transplant in patients with multiple myeloma.]]></description>
  </item>
  <item>
  <title>April 2006 Links Commentary</title>
  <pubDate>Mon, 24 Apr 2006 09:41:07 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_page.adp?item_id=410646</link>
  <description><![CDATA[This month, I am going to talk about the clinical trials that are essential to developing better ways to diagnose, treat and someday even prevent blood]]></description>
  </item>
  <item>
  <title>Defining Cancer by Genes, Not Organs, Suggests New Treatments</title>
  <pubDate>Thu, 20 Apr 2006 10:00:55 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=411898&amp;cat_id=140</link>
  <description><![CDATA[According to the Wall Street Journal, cancer has long been defined by where it is found in the body. In a significant shift, researchers are coming to believe that cancer comprises hundreds of subgroups based more on genetic makeup than location. This new thinking means that instead of focusing cancer treatment on organs, the emphasis increasingly is going to be on finding the specific genetic changes driving a person's cancer and targeting them with drugs.]]></description>
  </item>
  <item>
  <title>Patients with Stage IV Follicular Lymphoma Are Living Longer</title>
  <pubDate>Wed, 12 Apr 2006 10:42:22 EST</pubDate>
  <link>http://www.leukemia-lymphoma.org/all_news_detail?item_id=411049&amp;cat_id=140</link>
  <description><![CDATA[Researchers at The University of Texas M.D. Anderson Cancer Center in Houston evaluated trends over time in the survival of patients with stage IV follicular lymphoma; they found that survival improved notably between 1972 and 2002.]]></description>
  </item>
</channel>
</rss>
